(11) **EP 1 146 892 B1**(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**20.08.2003 Bulletin 2003/34**

(21) Application number: **00909970.6**

(22) Date of filing: **25.01.2000**

(51) Int Cl.7: **A61K 38/17**, A61K 39/395,  
A61K 48/00, A61P 9/00,  
A61P 9/12, A61P 13/12,  
A61P 35/00, A61P 31/18,  
A61P 37/02

(86) International application number:  
**PCT/US00/01788**

(87) International publication number:  
**WO 00/043032 (27.07.2000 Gazette 2000/30)**

(54) **BAFF, INHIBITORS THEREOF AND THEIR USE IN THE MODULATION OF THE B-CELL RESPONSE**

BAFF, DESSEN INHIBITOREN UND DESSEN VERWENDUNG ZUR MODULIERUNG DER  
B-ZELL-ANTWORT

BAFF, AGENTS BLOQUANTS ASSOCIES ET UTILISATION DE CEUX-CI POUR STIMULER ET  
INHIBER LA REPOSE IMMUNITAIRE DES LYMPHOCYTES B ET DES IMMUNOGLOBULINES

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **25.01.1999 US 117169 P**  
**09.07.1999 US 143228 P**

(43) Date of publication of application:  
**24.10.2001 Bulletin 2001/43**

(73) Proprietors:  

- **BIOGEN, INC.**  
Cambridge Massachusetts 02142 (US)
- **Apoxis SA**  
1066 Epalinges (CH)

(72) Inventors:  

- **BROWNING, Jeffrey**  
Brookline, MA 02146 (US)
- **AMBROSE, Christine**  
Reading, MA 01867 (US)
- **MACKAY, Fabienne**  
Vaucluse, NSW 2030 (AU)
- **TSCHOPP, Jurg**  
CH-1066 Epalinges (CH)
- **SCHNEIDER, Pascal**  
CH-1066 Epalinges (CH)

(74) Representative: **VOSSIUS & PARTNER**  
**Siebertstrasse 4**  
**81675 München (DE)**

(56) References cited:  

- **SCHNEIDER P ET AL:** "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth." JOURNAL OF EXPERIMENTAL MEDICINE, (1999 JUN 7) 189 (11) 1747-56. , XP000915409
- **MACKAY F ET AL:** "Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations." JOURNAL OF EXPERIMENTAL MEDICINE, (1999 DEC 6) 190 (11) 1697-710. , XP000915435
- **MUKHOPADHYAY A ET AL:** "Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase." JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 JUN 4) 274 (23) 15978-81. , XP002142251
- **MOORE P A ET AL:** "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator." SCIENCE, (1999 JUL 9) 285 (5425) 260-3. , XP002142252

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 146 892 B1

- KHARE S D ET AL: "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2000 MAR 28) 97 (7) 3370-5. , XP002142253

- GROSS J A ET AL: "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease [see comments]." NATURE, (2000 APR 27) 404 (6781) 995-9. , XP002142254

## Description

**FIELD OF THE INVENTION**

**[0001]** The present invention relates to the use of a ligand BAFF, a  $\beta$ -cell activating factor belonging to the Tumor Necrosis Family and its blocking agents to either stimulate or inhibit the expression of B-cells and immunoglobulins. This protein and its receptor may be useful for anti-cancer and/or immunoregulatory applications as well as for the treatment of immunosuppressive disorders such as HIV. Specifically, the ligand and its blocking agents may play a role in the development of hypertension and its related disorders. Furthermore, cells transfected with the gene for this ligand may be useful in gene therapy to treat tumors, autoimmune diseases or inherited genetic disorders involving B-cells. Blocking agents, such as recombinant variants or antibodies specific to the ligand or its receptor, may be useful for immunoregulatory applications as well. Use of BAFF for the manufacture of a medicament for stimulating B-cell growth for immune suppressed diseases including for example uses for patients undergoing organ transplantation (ie bone marrow transplant) as well as recovering from cancer treatments to stimulate production of B-cells are contemplated.

**BACKGROUND OF THE INVENTION**

**[0002]** The tumor-necrosis factor (TNF)-related cytokines are mediators of host defense and immune regulation. Members of this family exist in membrane-anchored forms, acting locally through cell-to-cell contact, or as secreted proteins capable of diffusing to more distant targets. A parallel family of receptors signals the presence of these molecules leading to the initiation of cell death or cellular proliferation and differentiation in the target tissue. Presently, the TNF family of ligands and receptors has at least 11 recognized receptor-ligand pairs, including: TNF:TNF-R; LT- $\alpha$ :TNP-R; LT- $\alpha$ / $\beta$ :LT- $\beta$ -R; FasL:Fas; CD40L:CD40; CD30L:CD30; CD27L:CD27; OX40L:OX40 and 4-1BBL:4-1BB. The DNA sequences encoding these ligands have only about 25% to about 30% identity in even the most related cases, although the " amino acid relatedness is about 50%.

**[0003]** The defining feature of this family of cytokine receptors is found in the cysteine rich extracellular domain initially revealed by the molecular cloning of two distinct TNF receptors. This family of genes encodes glycoproteins characteristic of Type I transmembrane proteins with an extracellular ligand binding domain, a single membrane spanning region and a cytoplasmic region involved in activating cellular functions. The cysteine-rich ligand binding region exhibits a tightly knit disulfide linked core domain, which, depending upon the particular family member, is repeated multiple times. Most receptors have four domains, although there may be as few as three, or as many as six.

**[0004]** Proteins in the TNF family of ligands are characterized by a short N-terminal stretch of normally short hydrophilic amino acids, often containing several lysine or arginine residues thought to serve as stop transfer sequences. Next follows a transmembrane region and an extracellular region of variable length, that separates the C-terminal receptor binding domain from the membrane. This region is sometimes referred to as the "stalk". The C-terminal binding region comprises the bulk of the protein, and often, but not always, contains glycosylation sites. These genes lack the classic signal sequences characteristic of type I membrane proteins, type II membrane proteins with the C terminus lying outside the cell, and a short N-terminal domain residing in the cytoplasm. In some cases, e.g., TNF and LT- $\alpha$ , cleavage in the stalk region can occur early during protein processing and the ligand is then found primarily in secreted form. Most ligands, however, exist in a membrane form, mediating localized signaling.

**[0005]** The structure of these ligands has been well-defined by crystallographic analyses of TNF, LT- $\alpha$ , and CD40L. TNF and lymphotoxin- $\alpha$  (LT- $\alpha$ ) are both structured into a sandwich of two anti-parallel  $\beta$ -pleated sheets with the "jelly roll" or Greek key topology. The rms deviation between the C $\alpha$  and  $\beta$  residues is 0.61 Å, suggesting a high degree of similarity in their molecular topography. A structural feature emerging from molecular studies of CD40L, TNF and LT- $\alpha$  is the propensity to assemble into oligomeric complexes. Intrinsic to the oligomeric structure is the formation of the receptor binding site at the junction between the neighboring subunits creating a multivalent ligand. The quaternary structures of TNF, CD40L and LT- $\alpha$  have been shown to exist as trimers by analysis of their crystal structures. Many of the amino acids conserved between the different ligands are in stretches of the scaffold  $\beta$ -sheet. It is likely that the basic sandwich structure is preserved in all of these molecules, since portions of these scaffold sequences are conserved across the various family members. The quaternary structure may also be maintained since the subunit conformation is likely to remain similar.

**[0006]** TNF family members can best be described as master switches in the immune system controlling both cell survival and differentiation. Only TNF and LT $\alpha$  are currently recognized as secreted cytokines contrasting with the other predominantly membrane anchored members of the TNF family. While a membrane form of TNF has been well-characterized and is likely to have unique biological roles, secreted TNF functions as a general alarm signaling to cells more distant from the site of the triggering event. Thus TNF secretion can amplify an event leading to the well-described changes in the vasculature lining and the inflammatory state of cells. In contrast, the membrane bound members of the family send signals through the TNF type receptors only to cells in direct contact. For example T cells provide CD40

mediated "help" only to those B cells brought into direct contact via cognate TCR interactions. Similar cell-cell contact limitations on the ability to induce cell death apply to the well-studied Fas system.

**[0007]** It appears that one can segregate the TNF ligands into three groups based on their ability to induce cell death. First, TNF, Fas ligand and TRAIL can efficiently induce cell death in many lines and their receptors mostly likely have good canonical death domains. Presumably the ligand to DR-3 (TRAMP/WSL-1) would also all into this category. Next there are those ligands which trigger a weaker death signal limited to few cell types and TWEAK, CD30 ligand and LTa1b2 are examples of this class. How this group can trigger cell death in the absence of a canonical death domain is an interesting question and suggests that a separate weaker death signaling mechanism exists. Lastly, there are those members that cannot efficiently deliver a death signal. Probably all groups can have antiproliferative effects on some cell types consequent to inducing cell differentiation e.g. CD40. Funakoshi et al. (1994).

**[0008]** The TNF family has grown dramatically in recent years to encompass at least 11 different signaling pathways involving regulation of the immune system. The widespread expression patterns of TWEAK and TRAIL indicate that there is still more functional variety to be uncovered in this family. This aspect has been especially highlighted recently in the discovery of two receptors that affect the ability of rous sarcoma and herpes simplex virus to replicate as well as the historical observations that TNF has anti-viral activity and pox viruses encode for decoy TNF receptors. Brojatsch et al. (1996); Montgomery et al. (1996); Smith et al. (1994), 76 *Cell* 959-962; Vassalli et al. (1992), 10 *Immunol.* 411-452.

**[0009]** TNF is a mediator of septic shock and cachexia, and is involved in the regulation of hematopoietic cell development. It appears to play a major role as a mediator of inflammation and defense against bacterial, viral and parasitic infections as well as having antitumor activity. TNF is also involved in different autoimmune diseases. TNF may be produced by several types of cells, including macrophages, fibroblasts, T cells and natural killer cells. TNF binds to two different receptors, each acting through specific intracellular signaling molecules, thus resulting in different effects of TNF. TNF can exist either as a membrane bound form or as a soluble secreted cytokine.

**[0010]** LT- $\alpha$  shares many activities with TNF, i.e. binding to the TNF receptors, but unlike TNF, appears to be secreted primarily by activated T cells and some  $\beta$ -lymphoblastoid tumors. The heteromeric complex of LT- $\alpha$  and LT- $\beta$  is a membrane bound complex which binds to the LT- $\beta$  receptor. The LT system (LTs and LT-R) appears to be involved in the development of peripheral lymphoid organs since genetic disruption of LT- $\beta$  leads to disorganization of T and B cells in the spleen and an absence of lymph nodes. The LT- $\beta$  system is also involved in cell death of some adenocarcinoma cell lines.

**[0011]** Fas-L, another member of the TNF family, is expressed predominantly on activated T cells. It induces the death of cells bearing its receptor, including tumor cells and HIV-infected cells, by a mechanism known as programmed cell death or apoptosis. Furthermore, deficiencies in either Fas or Fas-L may lead to lymphoproliferative disorders, confirming the role of the Fas system in the regulation of immune responses. The Fas system is also involved in liver damage resulting from hepatitis chronic infection and in autoimmunity in HIV-infected patients. The Fas system is also involved in T-cell destruction in HIV patients. TRAIL, another member of this family, also seems to be involved in the death of a wide variety of transformed cell lines of diverse origin.

**[0012]** CD40-L, another member of the TNF family, is expressed on T cells and induces the regulation of CD40-bearing B cells. Furthermore, alterations in the CD40-L gene result in a disease known as X-linked hyper-IgM syndrome. The CD40 system is also involved in different autoimmune diseases and CD40-L is known to have antiviral properties. Although the CD40 system is involved in the rescue of apoptotic B cells, in non-immune cells it induces apoptosis. Many additional lymphocyte members of the TNF family are also involved in costimulation.

**[0013]** Generally, the members of the TNF family have fundamental regulatory roles in controlling the immune system and activating acute host defense systems. Given the current progress in manipulating members of the TNF family for therapeutic benefit, it is likely that members of this family may provide unique means to control disease. Some of the ligands of this family can directly induce the apoptotic death of many transformed cells e.g. LT, TNF, Fas ligand and TRAIL. Nagata (1997) 88 *Cell* 355-365. Fas and possibly TNF and CD30 receptor activation can induce cell death in nontransformed lymphocytes which may play an immunoregulatory function. Amakawa et al. (1996) 84 *Cell* 551-562; Nagata (1997) 88 *Cell* 355-365; Sytwu et al. (1996); Zheng et al. (1995) 377 *Nature* 348-351. In general, death is triggered following the aggregation of death domains which reside on the cytoplasmic side of the TNF receptors. The death domain orchestrates the assembly of various signal transduction components which result in the activation of the caspase cascade. Nagata (1997) 88 *Cell* 355-365. Some receptors lack canonical death domains, e.g. LT $\beta$  receptor and CD30 (Browning et al. (1996); Lee et al. (1996)) yet can induce cell death, albeit more weakly. It is likely that these receptors function primarily to induce cell differentiation and the death is an aberrant consequence in some transformed cell lines, although this picture is unclear as studies on the CD30 null mouse suggest a death role in negative selection in the thymus. Amakawa et al. (1996) 84 *Cell* 551-562. Conversely, signaling through other pathways such as CD40 is required to maintain cell survival. Thus, there is a need to identify and characterize additional molecules which are members of the TNF family thereby providing additional means of controlling disease and manipulating the immune system.

**[0014]** Here we characterize the functional properties of a new ligand of the TNF cytokine family. The new ligand,

termed BAFF (B cell activating factor belonging to the TNF family), appears to be expressed by T cells and dendritic cells for the purpose of B-cell co-stimulation and may therefore play an important role in the control of B cell function. In addition, we have generated transgenic mice overexpressing BAFF under the control of a liver-specific promoter. These mice have excessive numbers of mature B cells, spontaneous germinal center reactions, secrete autoantibodies, and have high plasma cell numbers in secondary lymphoid organs and Ig deposition in the kidney.

# SUMMARY OF THE INVENTION

[0015] Accordingly, the present invention is directed to the use of the ligand BAFF blocking agents and antibodies for the ligand, for the manufacture of a pharmaceutical composition to either stimulate or inhibit the growth of B-cells and the secretion of immunoglobulin. The claimed invention may be used for therapeutic applications in numerous diseases and disorders, as discussed in more detail below, as well as to obtain information about, and manipulate, the immune system and its processes. Further, this invention can be used for stimulating or inhibiting the growth of B-cells and the secretion of immunoglobulins. BAFF associated molecules, as described by this invention, may also have utility in the treatment of autoimmune diseases, disorders relating to B-cell proliferation and maturation, BAFF regulation and inflammation. The invention may be involved in the regulation or prevention of hypertension and hypertension-related disorders of the renal and cardiovascular tissue.

[0016] Additional features and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The objectives and other advantages of the invention will be realized and attained by the methods particularly pointed out in the written description and claims hereof, as well as in the appended drawings.

[0017] Thus, to achieve these and other advantages, and in accordance with the purpose of the invention, as embodied and broadly described herein, the invention includes the use of various ligands BAFF and related molecules effecting B-cell growth and secretion of immunoglobulins.

[0018] The invention also contemplates the use of BAFF or active fragments of the polypeptide for the manufacture of a pharmaceutical composition for stimulating B-cell growth. The polypeptide may be used alone or with a CD40 ligand or an anti-murine antibody.

[0019] In other embodiments, the invention relates to the use of BAFF or active fragments of BAFF for the manufacture of a pharmaceutical composition for the stimulation of dendritic cell-induced B-cell growth and maturation. Again, the polypeptide may be used alone or with CD40 ligand or anti- $\mu$  antibodies.

[0020] In other embodiments, blocking agents of BAFF and the BAFF receptor have been used for the manufacture of a pharmaceutical composition for inhibiting B-cell growth and immunoglobulin secretion. These agents can be inoperable, recombinant BAFF, BAFF specific antibodies, or BAFF-receptor specific antibodies.

[0021] In yet other embodiments, the invention relates to the use of BAFF, BAFF related molecules and BAFF blocking agents for the manufacture of a pharmaceutical composition for treating hypertension, hypertension related disorders, immune disorders, autoimmune diseases, inflammation and B-cell lympho-proliferate disorders.

[0022] The invention encompasses the use of BAFF and BAFF-related molecules as either agonists or antagonists for the manufacture of a pharmaceutical composition for effecting immune responses by effecting the growth and/or maturation of B-cells and secretion of immunoglobulin.

[0023] The invention relates in other embodiments to soluble constructs comprising BAFF which may be used to directly trigger BAFF mediated pharmacological events. Such events may have useful therapeutic benefits in the treatment of cancer, tumors or the manipulation of the immune system to treat immunologic diseases.

[0024] Additionally, in other embodiments the claimed invention relates to antibodies directed against BAFF which can be used, for example for the manufacture of a pharmaceutical composition for the treatment of cancers, and manipulation of the immune system to treat immunologic disease.

[0025] In yet other embodiments the invention relates to gene therapy using the genes for BAFF.

[0026] The pharmaceutical preparations of the invention may, optionally, include pharmaceutically acceptable carriers, adjuvants, fillers, or other pharmaceutical compositions, and may be administered in any of the numerous forms or routes known in the art.

[0027] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory, and are intended to provide further explanation of the invention as claimed.

[0028] The accompanying drawings are included to provide a further understanding of the invention, and are incorporated in, and constitute a part of this specification, illustrate several embodiments of the invention, and together with the description serve to explain the principles of the invention.

**DESCRIPTION OF THE DRAWINGS****[0029]**

Figure 1 (A) depicts the predicted amino acid sequence of human and mouse BAFF. The predicted transmembrane domain (TMD, dashed line), the potential N-linked glycosylation sites (stars) and the natural processing site of human BAFF (arrow) are indicated. The double line above hBAFF indicates the sequence obtained by Edman degradation of the processed form of BAFF. (B) Depicts a comparison of the extracellular protein sequence of BAFF and some members of the TNF ligand family. Identical and homologous residues are represented in black and shaded boxes, respectively. (C) Depicts dendrogram of TNF family ligands

Figure 2 is a schematic characterization of recombinant BAFF (A) Schematic representation of recombinant BAFF constructs. Soluble recombinant BAFFs starting at Leu<sub>83</sub> and Gln<sub>136</sub> are expressed fused to a N-terminal Flag tag and a 6 amino acid linker. The long form is cleaved between Arg<sub>133</sub> and Ala<sub>134</sub> (arrow) in 293 T cells, to yield a processed form of BAFF. Asn<sub>124</sub> and Asn<sub>242</sub> belong to N-glycosylation consensus sites. N-linked glycan present on Asn<sub>124</sub> is shown as a Y. TMD: transmembrane domain. (B) Peptide N-glycanase F (PNGase F) treatment of recombinant BAFF. Concentrated supernatants containing Flag-tagged BAFFs and APRIL were deglycosylated and analyzed by Western blotting using polyclonal anti-BAFF antibodies or anti-Flag M2, as indicated. All bands except processed BAFF also reacted with anti-Flag M2 (data not shown). (C) Full length BAFF is processed to a soluble form. 293T cells were transiently transfected with full length BAFF. Transfected cells and their concentrated supernatants were analyzed by Western blotting using polyclonal anti-BAFF antibodies. Supernatants corresponding to 10 x the amount of cells were loaded onto the gel. (D) Size exclusion chromatography of soluble BAFF on Superdex-200. Concentrated supernatants containing soluble BAFF/short were fractionated on a Superdex-200 column and the eluted fractions analyzed by Western blotting using anti-Flag M2 antibody. The migration positions of the molecular mass markers (in kDa) are indicated on the left-hand side for SDS-PAGE and at the top of the figure for size exclusion chromatography.

Figure 3 depicts expression of BAFF (A) Northern blots (2 µg poly A<sup>+</sup> RNA per lane) of various human tissues were probed with BAFF antisense mRNA. (B) Reverse transcriptase amplification of BAFF, IL-2 receptor alpha chain and actin from RNA of purified blood T cells at various time points of PHA activation, E-rosetting negative blood cells (B cells and monocytes), *in vitro* derived immature dendritic cells, 293 cells, and 293 cells sterily transfected with full length BAFF (293-BAFF). Control amplifications were performed in the absence of added cDNA. IL-2 receptor alpha chain was amplified as a marker of T cell activation.

Figure 4 depicts BAFF binding to mature B cells. (A) Binding of soluble BAFF to BJAB and Jurkat cell lines, and to purified CD19<sup>+</sup> cells of cord blood. Cells were stained with the indicated amount (in ng/50 µl) of Flag-BAFF and analyzed by flow cytometry. (B) Binding of soluble BAFF to PBLs. PBLs were stained with anti-CD8-FITC or with anti-CD19-FITC (horizontal axis) and with Flag-BAFF plus M2-biotin and avidin-PE (vertical axis). Flag-BAFF was omitted in controls.

Figure 5 depicts BAFF costimulates B cell proliferation. (A) Surface expression of BAFF in stably transfected 293 cells. 293-BAFF and 293 wild-type cells were stained with anti-BAFF mAb 43.9 and analyzed by flow cytometry. (B) Costimulation of PBLs by 293-BAFF cells. PBLs (10<sup>5</sup>/well) were incubated with 15.000 glutaraldehyde-fixed 293 cells (293 wt or 293-BAFF) in the presence or absence of anti-B cell receptor antibody (anti-µ). Fixed 293 cells alone incorporated 100 cpm. (C) Dose dependent costimulation of PBL proliferation by soluble BAFF in the presence of anti-µ.

Proliferation was determined after 72 h incubation by [<sup>3</sup>H]-thymidine incorporation. Controls include cells treated with BAFF alone, with heat-denatured BAFF or with an irrelevant isotype matched antibody in place of anti-µ. (D) Comparison of (co)stimulatory effects of sCD40L and sBAFF on PBL proliferation. Experiment was performed as described in panel C. (E) BAFF costimulates Ig secretion of preactivated human B cells. Purified CD19<sup>+</sup> B cells were activated by coculture with EL-4 T cells and activated T cell supernatants for 5-6 d, then re-isolated and cultured for another 7 days in the presence of medium only (-) or containing 5% activated T cell supernatants (T-SUP) or a blend of cytokines (IL-2, IL-4, IL-10). The columns represent means of Ig concentrations for cultures with or without 1 µg/ml BAFF. Means ± SD in terms of "fold increase" were 1.23 ± 0.11 for medium only, 2.06 ± 0.18 with T cell supernatants (4 experiments) and 1.45 ± 0.06 with IL-2, IL-4 and IL-10 (2 experiments). These were performed with peripheral blood (3 experiments) or cord blood B cells (one experiment; 2.3 fold increase with T cell supernatants, 1.5 fold increase with IL-2, IL-4 and IL-10). (F) Dose-response curve for the effect of BAFF in cultures with T cell supernatants, as shown in panel D. Mean ± SD of 3 experiments.

Figure 6 depicts that BAFF acts as a cofactor for B cell proliferation. The proliferation of human PBL was measured alone (500 cpm), with the presence of ligand BAFF alone, with the presence of goat anti-murine ( $\mu$ ) alone, and with both ligand BAFF and anti- $\mu$ . The combination of both anti- $\mu$  and BAFF significantly raised proliferation of PBL as the concentration of BAFF increased suggesting BAFF's cofactor characteristics.

Figure 7 depicts increased B cell numbers in BAFF Tg mice.

(A) Increased lymphocytes counts in BAFF Tg mice. The graph compares 12 control littermates (left panel) with 12 BAFF Tg mice (right panel). Lymphocytes counts are shown with circles and granulocytes (including neutrophils, eosinophils, basophils) with diamonds.

(B) Increased proportion of B cells in PBL from BAFF Tg mice. PBL were stained with both anti-B220-FITC and anti-CD4-PE for PACS analysis and gated on live cells using the forward side scatter. Percentages of CD4 and B220 positive cells are indicated. One control mouse (left) and two BAFF Tg mice (right) are shown and the results were representative of 7 animals analysed in each group.

(C) FACS analysis of the ratio of B to T cells in PBL. The difference between control animals and BAFF Tg mice in (A) and (C) was statistically significant ( $P < 0.001$ ).

(D) Increased MHC class II expression on B cells from BAFF Tg mice PBL. MHC class II expression was analysed by FACS.

(E) Increased Bcl-2 expression in B cells from BAFF Tg mice PBL. Bcl-2 expression was measured by intracytoplasmic staining and cells were analysed by FACS.

In both (D) and (E) Live cells were gated on the forward side scatter. Four control littermates (white bars) and 4 BAFF Tg mice are shown and are representative of at least 12 animals analysed for each group. MFI: mean of fluorescence intensity. The difference between control animals and BAFF Tg mice was statistically significant ( $P < 0.005$ ).

(F) Increased expression of effector T cells in BAFF Tg mice. PBL were stained with anti-CD4-Cychrome, anti-CD44-FITC and anti-L selectin-PE. Are shown CD4<sup>+</sup>-gated cells. Percentages of CD44<sup>hi</sup>/L-selectin<sup>lo</sup> cells are indicated. One control mouse (left) and two BAFF Tg mice (right) are shown and the results were representative of 8 animals analysed in each group.

Figure 8 depicts increased B cell compartments in the spleen but not in the bone marrow of BAFF Tg mice.

(A) FACS staining for mature B cells using both anti-IgM-FTTC and anti-B220-PE, in spleen (top panel), bone marrow (medium panel) and MLN (bottom panel). Percentages of B220<sup>+</sup>/IgM<sup>+</sup> mature B cells are indicated.

(B) FACS staining for preB cells (B220<sup>+</sup>/CD43<sup>-</sup>) and proB cells (B220<sup>+</sup>/CD43<sup>+</sup>) in the bone marrow using anti-CD43-FTTC, anti-B220-Cy-chrome and anti-IgM-PE simultaneously. Are shown cells gated on the IgM negative population. Percentages of preB cells (B220<sup>+</sup>/CD43<sup>-</sup>) and proB cells (B220<sup>+</sup>/CD43<sup>+</sup>) cells are indicated. For all figures (A and B) one control mouse (left) and two BAFF Tg mice (right) are shown and results are representative of 7 animals analysed for each group.

Figure 9 depicts increased Ig, RF and CIC levels in BAFF Tg mice

(A) SDS-PAGE of two control sera (-) and 4 sera from BAFF Tg mice (+) side by side with the indicated amount of a purified mouse IgG for reference. The intensity of the albumin band is similar in all lanes indicating that the material loaded on the gel is equivalent for each sample.

ELISA-based analysis of total mouse Ig (B), RF (C) and CIC (D) in the sera of 19 control littermates (white bars) and 21 BAFF Tg mice (Black bars). In the absence of a proper RF control, the titer (log base 2) for RF is defined as the dilution of the sera giving an O.D. 3 times higher than that of background. The quantity of CIC is defined as the quantity of PAP required to generate an O.D. equivalent to that obtained with the tested serum. The difference between control animals and BAFF Tg mice was statistically significant ( $P < 0.001$  in (B) and (C),  $P < 0.003$  in (D)).

Figure 10 depicts the presence of anti-ssDNA and anti-dsDNA autoantibodies in some BAFF Tg mice.

(A) Analysis by ELISA of anti-ssDNA autoantibodies in 19 control littermates (gray bars) and 21 BAFF Tg mice (black bars).

(B) Analysis by ELISA of anti-ssDNA autoantibodies in 5 control littermates and the 5 animals showing levels of anti-ssDNA autoantibodies from (A).

(C) Paraffin sections of kidneys from a control mouse (left) and a BAFF Tg mouse (right), stained with goat

anti-mouse Ig-HRP. Ig deposition is shown by a brown staining. These pictures are representative of 6 BAFF Tg mice analysed.

Figure 11 depicts enlarged Peyer's patches in GAFF Tg mice.

5      Photography of Peyer's patches (indicated with an arrow) on the small intestine of a control mouse (left) and a BAFF Tg mouse (right). This pictures is representative of at least 12 mice sacrificed for each group. Magnification 5X

10      Figure 12 depicts disrupted T and B cell organization, intense germinal center reactions, decreased number of dendritic cells and increased number of plasma cells in the spleen of BAFF Tg mice.

A control mouse is shown in A C, E and G and a BAFF Tg in B, D, F, and H. B cells are blue and T cells brown (A and B). Germinal centers as shown with an arrow (C and D). Only few residual germinal centers are seen in control mice (C). CD11c positive dendritic cells are brown and appear in the T cell zone, bridging channels and the marginal zone (E). Very few are present in BAFF Tg mice (F). Syndecan-1-positive plasma cells were only detectable in the red pulp of BAFF Tg mice (H) but not control mice (G).

15      These pictures are representative of at least 12 BAFF Tg mice analysed and 12 control mice. The magnification is 100X for all pictures except C and D which are 50X. B: B cell follicle, T: PALS, WP: white pulp, RP: red pulp.

20      Figure 13 depicts disrupted T and B cells organization, intense germinal center reactions and large number of plasma cells in the MLN of BAFF Tg mice.

The control mouse is shown in A, C, E and G and the BAFF Tg mouse is shown in B, D, F, and H. The immunohistochemistry was performed as described in figure 6. T and B cell staining is shown in A and B, germinal centers in C and D, dendritic cells E and F and plasma cells in G and H. GC: germinal center. Magnification 100X.

## 25      **DETAILED DESCRIPTION OF THE INVENTION**

[0030] Reference will now be made in detail to the present preferred embodiments of the invention. This invention relates to the use of BAFF and BAFF related molecules for the manufacture of a pharmaceutical composition for effecting the growth and maturation of B-cells and the secretion of immunoglobulin. The invention relates to the use of BAFF and BAFF related molecules for the manufacture of a pharmaceutical composition for effecting responses of the immune system, as necessitated by immune-related disorders. Additionally, this invention encompasses the use of a BAFF, or BAFF related gene, for the manufacture of a pharmaceutical composition for the treatment of cancer and immune disorders also through gene therapy methods.

30      [0031] The ligand BAFF and homologs thereof produced by hosts transformed with the sequences of the invention, as well as native BAFF purified by the processes known in the art, or produced from known amino acid sequences, are useful in a variety of methods for anticancer, antitumor and immunoregulatory applications. They are also useful in therapy and methods directed to other diseases.

[0032] Another aspect of the invention relates to the use of the polypeptide encoded by the isolated nucleic acid encoding the ligand BAFF for the manufacture of a pharmaceutical composition for "antisense" therapy. As used herein, "antisense" therapy refers to administration or *in situ* generation of oligonucleotides or their derivatives which specifically hybridize under cellular conditions with the cellular mRNA and/or DNA encoding the ligand of interest, so as to inhibit expression of the encoded protein, i.e. by inhibiting transcription and/or translation. The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" therapy refers to a range of techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences.

40      [0033] An antisense construct of the present invention can be delivered, for example, as an expression plasmid, which, when transcribed in the cell, produces RNA which is complementary to at least a portion of the cellular mRNA which encodes Kay-ligand. Alternatively, the antisense construct can be an oligonucleotide probe which is generated ex vivo. Such oligonucleotide probes are preferably modified oligonucleotides which are resistant to endogenous nucleases, and are therefore stable in vivo. Exemplary nucleic acids molecules for use as antisense oligonucleotides are phosphoramidates, phosphothioate and methylphosphonate analogs of DNA (See, e.g., U.S. Patent 5,176,996; U.S. Patent 5,264,564; and U.S. Patent 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy have been reviewed, for example, by Van Der Krol et al., (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48: 2659-2668.

55

### C. The ligand BAFF

[0034] The ligand BAFF of the invention, as discussed above, is a member of the TNF family and is described in



PCT application number PCT/US98/19037 (WO99/12964). The protein, fragments or homologs thereof may have wide therapeutic and diagnostic applications.

[0035] The ligand BAFF is present primarily in the spleen and in peripheral blood lymphocytes, strongly indicating a regulatory role in the immune system. Comparison of the claimed ligand BAFF sequences with other members of the human TNF family reveals considerable structural similarity. All the proteins share several regions of sequence conservation in the extracellular domain.

[0036] Although the precise three-dimensional structure of the claimed ligand is not known, it is predicted that, as a member of the TNF family, it may share certain structural characteristics with other members of the family.

[0037] The novel polypeptides of the invention specifically interact with a receptor, which has not yet been identified. However, the peptides and methods disclosed herein enable the identification of receptors which specifically interact with the ligand BAFF or fragments thereof.

[0038] The claimed invention in certain embodiments includes the use peptides derived from the ligand BAFF which have the ability to bind to their receptors. Fragments of BAFF can be produced in several ways, e.g., recombinantly, by PCR, proteolytic digestion or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end or both ends of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments.

[0039] Polypeptide fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-moc or t-boc chemistry. For example, peptides and DNA sequences of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragment, or divided into overlapping fragments of a desired length. Methods such as these are described in more detail below.

#### Generation of Soluble Forms of the ligand BAFF

[0040] Soluble forms of the BAFF-ligand can often signal effectively and hence can be administered as a drug which now mimics the natural membrane form. It is possible that the ligand BAFF claimed herein are naturally secreted as soluble cytokines, however, if not, one can reengineer the gene to force secretion. To create a soluble secreted form of BAFF one would remove at the DNA level the N-terminus transmembrane regions, and some portion of the stalk region, and replace them with a type I leader or alternatively a type II leader sequence that will allow efficient proteolytic cleavage in the chosen expression system. A skilled artisan could vary the amount of the stalk region retained in the secretion expression construct to optimize both receptor binding properties and secretion efficiency. For example, the constructs containing all possible stalk lengths, i.e. N-terminal truncations, could be prepared such that proteins starting at amino acids 81 to 139 would result. The optimal length stalk sequence would result from this type of analysis.

#### E. Generation of Antibodies Reactive with the ligand BAFF

[0041] The invention also includes antibodies specifically reactive with the claimed ligand BAFF or its receptors. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers, or other techniques, well known in the art.

[0042] An immunogenic portion of BAFF or its receptors can be administered in the presence of an adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

[0043] In a preferred embodiment, the subject antibodies are immunospecific for antigenic determinants of BAFF or its receptors, (e.g. antigenic determinants of a polypeptide of SEQ. ID. NO.: 2, said sequence as described in PCT application number PCT/US98/19037 (WO99/12964) and is incorporated in its entirety herewith), or a closely related human or non-human mammalian homolog (e.g. 70, 80 or 90 percent homologous, more preferably at least 95 percent homologous). In yet a further preferred embodiment of the present invention, the anti-BAFF or anti-BAFF-receptor antibodies do not substantially cross react (i.e. react specifically) with a protein which is e.g., less than 80 percent homologous to SEQ. ID. NO.: 2 or 6 said sequence as described in PCT application number PCT/US98/19037 (WO99/12964); preferably less than 90 percent homologous with SEQ. ID. NO.: 2 said sequence as described in PCT application number PCT/US98/19037 (WO99/12964); and, most preferably less than 95 percent homologous with SEQ. ID. NO.: 2 said sequence as described in PCT application number PCT/US98/19037 (WO99/12964). By "not substantially cross react", it is meant that the antibody has a binding affinity for a non-homologous protein which is less than 10 percent, more preferably less than 5 percent, and even more preferably less than 1 percent, of the binding affinity for a protein of SEQ. ID. NO.: 2 said sequence as described in PCT application number PCT/US98/19037 (WO99/12964).

[0044] The term antibody as used herein is intended to include fragments thereof which are also specifically reactive

with BAFF or its receptors. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example,  $F(ab')_2$  fragments can be generated by treating antibody with pepsin. The resulting  $F(ab')_2$  fragment can be treated to reduce disulfide bridges to produce Fab' fragments. The antibodies of the present invention are further intended to include biospecific and chimeric molecules having anti-BAFF or anti-BAFF receptor activity. Thus, both monoclonal and polyclonal antibodies (Ab) directed against BAFF, Tumor-ligand and their receptors, and antibody fragments such as Fab' and  $F(ab')_2$ , can be used to block the action of the Ligand and their respective receptor.

[0045] Various forms of antibodies can also be made using standard recombinant DNA techniques. Winter and Milstein (1991) *Nature* 349: 293-299.

[0046] For example, chimeric antibodies can be constructed in which the antigen binding domain from an animal antibody is linked to a human constant domain (e.g. Cabilly et al., U.S. patent 4,816,567). Chimeric antibodies may reduce the observed immunogenic responses elicited by animal antibodies when used in human clinical treatments.

[0047] In addition, recombinant "humanized antibodies" which recognize BAFF or its receptors can be synthesized. Humanized antibodies are chimeras comprising mostly human IgG sequences into which the regions responsible for specific antigen-binding have been inserted. Animals are immunized with the desired antigen, the corresponding antibodies are isolated, and the portion of the variable region sequences responsible for specific antigen binding are removed. The animal-derived antigen binding regions are then cloned into the appropriate position of human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies minimize the use of heterologous (i.e. inter species) sequences in human antibodies, and thus are less likely to elicit immune responses in the treated subject.

[0048] Construction of different classes of recombinant antibodies can also be accomplished by making chimeric or humanized antibodies comprising variable domains and human constant domains (CR1, CH2, CH3) isolated from different classes of immunoglobulins. For example, antibodies with increased antigen binding site valencies can be recombinantly produced by cloning the antigen binding site into vectors carrying the human  $\gamma$  chain constant regions. Arianandam et al. (1993) *J. Exp. Med.*, 177: 1439-1450.

[0049] In addition, standard recombinant DNA techniques can be used to alter the binding affinities of recombinant antibodies with their antigens by altering amino acid residues in the vicinity of the antigen binding sites. The antigen binding affinity of a humanized antibody can be increased by mutagenesis based on molecular modeling. Queen et al., (1989) *Proc. Natl. Acad. Sci.* 86: 10029-33.

#### F. Generation of Analogs: Production of Altered DNA and Peptide Sequences

[0050] Analogs of BAFF can differ from the naturally occurring BAFF in amino acid sequence, or in ways that do not involve sequence, or both. Non-sequence modifications include in vivo or in vitro chemical derivatization of BAFF. Non-sequence modifications include, but are not limited to, changes in acetylation, methylation, phosphorylation, carboxylation or glycosylation.

[0051] Preferred analogs include BAFF biologically active fragments thereof, whose sequences differ from the sequence given in SEQ. ID NO. 2 said sequence as described in PCT application number PCT/US98/19037 (WO99/12964), by one or more conservative amino acid substitutions, or by one or more non-conservative amino acid substitutions, deletions or insertions which do not abolish the activity of BAFF. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g. substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and, phenylalanine, tyrosine.

#### G. Materials and Methods of the Invention

[0052] The anti-Flag M2 monoclonal antibody, biotinylated anti-Flag M2 antibody and the anti-Flag M2 antibody coupled to agarose were purchased from Sigma. Cell culture reagents were obtained from Life Sciences (Basel, Switzerland) and Biowhittaker (Walkersville, MD). Flag-tagged soluble human APRIL (residues K<sub>110</sub>-L<sub>250</sub>) was produced in 293 cells as described (10, 11). FITC-labeled anti-CD4, anti-CD8 and anti-CD19 antibodies were purchased from Pharmingen (San Diego, CA). Goat  $F(ab')_2$  specific for the  $Fc_{\gamma 2}$  fragment of human IgM were purchased from Jackson ImmunoResearch (West Grove, PA). Secondary antibodies were obtained from either Pharmingen or from Jackson ImmunoResearch and used at the recommended dilutions.

[0053] Human embryonic kidney 293 T (12) cells and fibroblast cell lines (Table 1) were maintained in DMEM containing 10% heat-inactivated fetal calf serum (FCS). Human embryonic kidney 293 cells were maintained in DMEM-nutrient mix F12 (1:1) supplemented with 2% FCS. T cell lines, B cell lines, and macrophage cell lines (Table 1) were grown in RPMI supplemented with 10% FCS. Molt-4 cells were cultivated in Iscove's medium supplemented with 10% FCS. Epithelial cell lines were grown in MEM-alpha medium containing 10% FCS, 0.5 mM non-essential amino acids,

10 mM Na-Hepes and 1 mM Na pyruvate. HUVECs were maintained in M199 medium supplemented with 20% FCS, 100 µg/ml of epithelial cell growth factor (Collaborative Research, Inotech, Dottikon, Switzerland) and 100 µg/ml of heparin sodium salt (Sigma). All media contained penicillin and streptomycin antibiotics. Peripheral blood leukocytes were isolated from heparinized blood of healthy adult volunteers by Ficoll-Paque (Pharmacia, Uppsala, Sweden) gradient centrifugation and cultured in RPMI, 10% FCS.

[0054] T cells were obtained from non-adherents PBLs by rosetting with neuraminidase-treated sheep red blood cells and separated from non-rosetting cells (mostly B cells and monocytes) by Ficoll-Paque gradient centrifugation. Purified T cells were activated for 24 h with phytohemagglutinin (Sigma) (1 µg/ml), washed and cultured in RPMI, 10% FCS, 20 U/ml of IL-2. CD14<sup>+</sup> monocytes were purified by magnetic cell sorting using anti-CD14 antibodies, goat anti-mouse-coated microbeads and a Minimacs™ device (Miltenyi Biotech), and cultivated in the presence of GM-CSF (800 U/ml, Leucomax®, Essex Chemie, Luzern, Switzerland) and IL-4 (20 ng/ml, Lucerna Chem, Luzern, Switzerland) for 5 d, then with GM-CSF, IL-4 and TNFα (200 U/ml, Bender, Vienna, Austria) for an additional 3 d to obtain a CD83<sup>+</sup>, dendritic cell-like population. Human B cells of >97% purity were isolated from peripheral blood or umbilical cord blood using anti-CD19 magnetic beads (M450, Dynal, Oslo, Norway) as described (13).

#### - Northern Blot Analysis

[0055] Northern blot analysis was carried out using Human Multiple Tissue Northern Blots I and II (Clontech #7760-1 and #7759-1). The membranes were incubated in hybridization solution (50% formamide, 2.5 x Denhardt's, 0.2% SDS, 10 mM EDTA, 2 x SSC, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 6.5, 200 µg/ml sonicated salmon sperm DNA) for 2 h at 60°C. Antisense RNA probe containing the nucleotides corresponding to amino acids 136-285 of hBAFF was heat-denatured and added at 2 x 10<sup>6</sup> cpm/ml in fresh hybridization solution. The membrane was hybridized 16 h at 62°C, washed once in 2 x SSC, 0.05% SDS (30 min at 25°C), once in 0.1 x SSC, 0.1% SDS (20 min at 65°C) and exposed at -70°C to X-ray films.

#### - Characterization of BAFF cDNA.

[0056] A partial sequence of human BAFF cDNA was contained in several EST clones (e. g. GenBank Accession numbers T87299 and AA166695) derived from fetal liver and spleen and ovarian cancer libraries. The 5' portion of the cDNA was obtained by 5'-RACE-PCR (Marathon-Ready cDNA, Clontech, Palo Alto, CA) amplification with oligonucleotides AP1 and JT1013 (5'-ACTGTTTCTTCTGGACCCTGAACGGC-3') using the provided cDNA library from a pool of human leukocytes as template, as recommended by the manufacturer. The resulting PCR product was cloned into PCR-0 blunt (Invitrogen, NV Leek, The Netherlands) and subcloned as EcoRI/PstI fragment into pT7T3 Pac vector (Pharmacia) containing EST clone T87299. Full-length hBAFF cDNA was therefore obtained by combining 5' and 3' fragments using the internal PstI site of BAFF. Sequence has been assigned GenBank accession number AF116456.

[0057] A partial 617 bp sequence of murine BAFF was contained in two overlapping EST clones (AA422749 and AA254047). A PCR fragment spanning nucleotides 158 to 391 of this sequence was used as a probe to screen a mouse spleen cDNA library (Stratagene, La Jolla, CA).

#### - Expression of recombinant BAFF

[0058] Full length hBAFF was amplified using oligos JT1069 (5'-GACAAGCTTGCCACCATGGATGACTCCACA-3') and JT637 (5'-ACTAGTCACAGCAGTTTCAATGC-3'). The PCR product was cloned into PCR-0 blunt and re-subcloned as HindIII/EcoRI fragment into PCR-3 mammalian expression vector. A short version of soluble BAFF (amino acids Q136-L285) was amplified using oligos JT636 (5'-CTGCAGGGTCCAGAAGAAACAG-3') and JT637. A long version of soluble BAFF (aa L83-L285) was obtained from full length BAFF using internal PstI site. Soluble BAFFs were resub-cloned as PstI/EcoRI fragments behind the haemagglutinin signal peptide and Flag sequence of a modified PCR-3 vector, and as PstI/SpeI fragments into a modified pQE16 bacterial expression vector in frame with a N-terminal Flag sequence (14). Constructs were sequenced on both strands. The establishment of stable 293 cell lines expressing the short soluble form or full length BAFF, and the expression and purification of recombinant soluble BAFF from bacteria and mammalian 293 cells was performed as described (14, 15).

#### - Reverse Transcriptase PCR

[0059] Total RNA extracted from T cells, B cells, *in vitro* derived immature dendritic cells, 293 wt and 293-BAFF (full length) cells was reverse transcribed using the Ready to Go system (Pharmacia) according to the manufacturer's instructions. BAFF and β-actin cDNAs were detected by PCR amplification with Taq DNA polymerase (steps of 1 min each at 94°C, 55°C and 72°C for 30 cycles) using specific oligonucleotides: for BAFF, JT1322 5'-GGAGAAGGCAACTC-CAGTCAGAAC-3' and JT1323 5'-CAATTCATCCCCAAAGACATGGAC-3'; for IL-2 receptor alpha chain, JT1368

5'-TCGGAACACAACGAAACAAGTC-3' and JT1369 5'-CTTCTCCTTCACCTGGAAACTGACTG-3'; for  $\beta$ -actin, 5'-GGCATCGTGATGGACTCCG-3' and 5'-GCTGGAAGGTGGACAGCGA-3'.

- Gel permeation chromatography

5

**[0060]** 293T cells were transiently transfected with the short form of soluble BAFF and grown in serum-free Optimum medium for 7 d. Conditioned supernatants were concentrated 20 x, mixed with internal standards catalase and ovalbumin, and loaded onto a Superdex-200 HR10/30 column. Proteins were eluted in PBS at 0.5 ml/min and fractions (0.25 ml) were precipitated with trichloroacetic acid and analyzed by Western blotting using anti-Flag M2 antibody. The column was calibrated with standard proteins: ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa), bovine serum albumine (67 kDa), ovalbumine (43 kDa), chymotrypsinogen A (25 kDa) and ribonuclease A (13.7 kDa).

10

- PNGase F treatment

15

**[0061]** Samples were heated in 20  $\mu$ l of 0.5% SDS, 1% 2-mercaptoethanol for 3 min at 95°C, then cooled and supplemented with 10% Nonidet P-40 (2  $\mu$ l), 0.5 M sodium phosphate, pH 7.5 (2  $\mu$ l) and Peptide N-glycanase F (125 units/ $\mu$ l, 1  $\mu$ l, or no enzyme in controls). Samples were incubated for 3h at 37°C prior to analysis by Western blotting.

- EDMAN sequencing

20

**[0062]** 293 T cells were transiently transfected with the long form of soluble BAFF and grown in serum-free Optimum medium for 7 d. Conditioned supernatants were concentrated 20 x, fractionated by SDS-PAGE and blotted onto polyvinylidene difluoride membrane (BioRad Labs, Hercules, CA) as previously described (16), and then sequenced using a gas phase sequencer (ABI 120A, Perkin Elmer, Foster City, CA) coupled to an analyzer (ABI 120A, Perkin Elmer) equipped with a phenylthiohydantoin C18 2.1 x 250 mm column. Data was analyzed using software ABI 610 (Perkin Elmer).

25

- Antibodies

30

**[0063]** Polyclonal antibodies were generated by immunizing rabbits (Eurogentec, Seraing, Belgium) with recombinant soluble BAFF. Spleen of rats immunized with the same antigen were fused to x63Ag8.653 mouse myeloma cells, and hybridoma were screened for BAFF-specific IgGs. One of these monoclonal antibodies, 43.9, is an IgG2a that specifically recognizes hBAFF.

35

**[0064]** Cells were stained in 50  $\mu$ l of FACS buffer (PBS, 10% FCS, 0.02%  $\text{NaN}_3$ ) with 50 ng (or the indicated amount) of Flag tagged short soluble hBAFF for 20 min at 4°C, followed by anti-Flag M2 (1  $\mu$ g) and secondary antibody. Anti-BAFF mAb 43.9 was used at 40  $\mu$ g/ml. For two color FACS analysis, peripheral blood lymphocytes were stained with Flag tagged soluble BAFF/long (2  $\mu$ g/ml), followed by biotinylated anti-Flag M2 (1/400) and PE-labeled streptavidin (1/100), followed by either FITC-labeled anti-CD4, anti-CD8 or anti-CD19.

40

- PBL proliferation assay

45

**[0065]** Peripheral blood leukocytes were incubated in 96-well plates ( $10^5$  cells/well in 100  $\mu$ l RPMI supplemented with 10% FCS) for 72 h in the presence or absence of 2  $\mu$ g/ml of goat anti-human  $\mu$  chain antibody (Sigma) or control F(ab')<sub>2</sub> and with the indicated concentration of native or boiled soluble BAFF/long. Cells were pulsed for an additional 6 h with [<sup>3</sup>H]thymidine (1  $\mu$ Ci/well) and harvested. [<sup>3</sup>H]thymidine incorporation was monitored by liquid scintillation counting. In some experiments, recombinant soluble BAFF was replaced by 293 cells stably transfected with full length BAFF (or 293 wt as control) that had been fixed for 5 min at 25°C in 1% paraformaldehyde. Assay was performed as described (17). In further experiments, CD19<sup>+</sup> cells were isolated from PBL with magnetic beads and the remaining CD19<sup>-</sup> cells were irradiated (3000 rads) prior to reconstitution with CD19<sup>+</sup> cells. Proliferation assay with sBAFF was then performed as described above.

50

- B cell activation assay

55

**[0066]** Purified B cells were activated in the EL-4 culture system as described (13). Briefly,  $10^4$  B cells mixed with  $5 \times 10^4$  irradiated murine EL-4 thymoma cells (clone B5) were cultured for 5-6 d in 200  $\mu$ l medium containing 5% v/v of culture supernatants from human T cells ( $10^6$ /ml) which had been activated for 48 h with PHA (1  $\mu$ g/ml) and PMA (1 ng/ml). B cells were then reisolated with anti-CD19 beads and cultured for another 7 d ( $5 \times 10^4$  cells in 200  $\mu$ l, duplicate or triplicate culture in flat bottomed 96 well plates) in medium alone or in medium supplemented with 5% T cell super-

natants, or with 50 ng/ml IL-2 (a kind gift from the former Glaxo Institute for Molecular Biology, Geneva) and 10 ng/ml each IL-4 and IL-10 (Peprotech, London, UK), in the presence or absence of sBAFF. The anti-Flag M2 antibody was added at a concentration of 2 µg/ml and had no effect by itself. IgM, IgG and IgA in culture supernatants were quantitated by ELISA assays as described (13).

**[0067]** Human BAFF was identified by sequence homology as a possible novel member of the TNF ligand family while we screened public databases using an improved profile search (18). A cDNA encoding the complete protein of 285 amino acids (aa) was obtained by combining EST-clones (covering the 3' region) with a fragment (5' region) amplified by PCR. The absence of a signal peptide suggested that BAFF was a type II membrane protein that is typical of the members of the TNF-ligand family. The protein has a predicted cytoplasmic domain of 46 aa, a hydrophobic transmembrane region, and an extracellular domain of 218 aa containing two potential N-glycosylation sites (Fig. 1A). The sequence of the extracellular domain of BAFF shows highest homology with APRIL (33 % amino acid identities, 48% homology), whereas the identity with other members of the family such as TNF, FasL, LT $\alpha$ , TRAIL or RANKL is below 20% (Fig. 1B, C). The mouse BAFF cDNA clone isolated from a spleen library encoded a slightly longer protein (309 aa) due to an insertion between the transmembrane region and the first of several  $\beta$ -strands which constitute the receptor binding domain in all TNF ligand members (19). This  $\beta$ -strand rich ectodomain is almost identical in mouse and human BAFF (86% identity, 93% homology) suggesting that the BAFF gene has been highly conserved during evolution (Fig. 1A).

**[0068]** Although TNF family members are synthesized as membrane inserted ligands, cleavage in the stalk region between transmembrane and receptor binding domain is frequently observed. For example, TNF or FasL are readily cleaved from the cell surface by metalloproteinases (20, 21). While producing several forms of recombinant BAFF in 293T cells, we noticed that a recombinant soluble 32 kDa form of BAFF (aa 83-285, sBAFF/long), containing the complete stalk region and a N-terminal Flag-tag in addition to the receptor binding domain, was extensively processed to a smaller 18 kDa fragment (Fig. 2A, B). Cleavage occurred in the stalk region since the fragment was detectable only with antibodies raised against the complete receptor interaction domain of BAFF but not with anti-Flag antibodies (data not shown). Also revealed was that only N124 (located in the stalk) but not N242 (located at the entry of the F- $\beta$  sheet) was glycosylated, since the molecular mass of the non-processed sBAFF/long was reduced from 32 kDa to 30 kDa upon removal of the N-linked carbohydrates with PNGase F whereas the 18 kDa cleaved form was insensitive to this treatment. Peptide sequence analysis of the 18 kDa fragment indeed showed that cleavage occurred between R133 and A 134 (Fig. 1A). R133 lies at the end of a polybasic region which is conserved between human (R-N-K-R) and mouse (R-N-R-R). To test whether cleavage was not merely an artifact of expressing soluble, non-natural forms of BAFF, membrane-bound full length BAFF was expressed in 293T cells (Fig. 2C). The 32 kDa complete BAFF and some higher molecular mass species (probably corresponding to non-dissociated dimers and trimers) were readily detectable in cellular extracts, but more than 95% of BAFF recovered from the supernatant corresponded to the processed 18 kDa form, indicating that BAFF was also processed when synthesized as a membrane-bound ligand.

**[0069]** A soluble BAFF was engineered (Q136-L285, sBAFF/short) whose sequence started 2 aa downstream of the processing site (Fig. 1 B). As predicted, the Flag-tag attached to the N-terminus of this recombinant molecule was not removed (data not shown) which allowed its purification by an anti-Flag affinity column. To test its correct folding, the purified sBAFF/short was analyzed by gel filtration where the protein eluted at an apparent molecular mass of 55 kDa (Fig. 2D). The sBAFF/short correctly assembles into a homotrimer (3 x 20 kDa) in agreement with the quaternary structure of other TNF family members (19). Finally, unprocessed sBAFF/long was readily expressed in bacteria, indicating that the cleavage event was specific to eukaryotic cells.

**[0070]** Northern blot analysis of BAFF revealed that the 2.5 kb BAFF mRNA was abundant in the spleen and PBLs (Fig. 3A). Thymus, heart, placenta, small intestine and lung showed weak expression. This restricted distribution suggested that cells present in lymphoid tissues were the main source of BAFF. Through PCR analysis, we found that BAFF mRNA was present in T cells and peripheral blood monocyte-derived dendritic cells but not in B cells (Fig. 3B). Even naive, non-stimulated T cells appeared to express some BAFF mRNA.

**[0071]** A sequence tagged site (STS, SHGC-36171) was found in the database which included the human BAFF sequence. This site maps to human chromosome 13, in a 9cM interval between the markers D13S286 und D13S1315. On the cytogenetic map, this interval corresponds to 13q32-34. Of the known TNF ligand family members, only RANKL (Trance) has been localized to this chromosome (22) though quite distant to BAFF (13q14).

**[0072]** In order for the ligand to exert maximal biological effects, it was likely that the BAFF receptor (BAFF-R) would be expressed either on the same cells or on neighboring cells present in lymphoid tissues. Using the recombinant sBAFF as a tool to specifically determine BAFF-R expression by FACS, we indeed found high levels of receptor expression in various B cell lines such as the Burkitt lymphomas Raji and BJAB (Fig. 4A, Table 1). In contrast, cell lines of T cell, fibroblastic, epithelial and endothelial origin were all negative. Very weak staining was observed with the monocyte line THP-1 which, however, could be due to Fc receptor binding. Thus, BAFF-R expression appears to be restricted to B cell lines. The two mouse B cell lines tested were negative using the human BAFF as a probe, although weak binding was observed on mouse splenocytes (data not shown). The presence of BAFF-R on B cells was corroborated

orated by analysis of umbilical cord and peripheral blood lymphocytes. While CD8<sup>+</sup> and CD4<sup>+</sup> T cells lacked BAFF-R (Fig. 4B and data not shown), abundant staining was observed on CD19<sup>+</sup> B cells (Fig. 4A and 4B), indicating that BAFF-R is expressed on all blood B cells, including naive and memory ones.

**[0073]** Since BAFF bound to blood-derived B cells, experiments were performed to determine whether the ligand could deliver growth-stimulatory or -inhibitory signals. Peripheral blood lymphocytes (PBL) were stimulated with anti-IgM ( $\mu$ ) antibodies together with fixed 293 cells stably expressing surface BAFF (Fig. 5A). The levels of [<sup>3</sup>H]thymidine incorporation induced by anti- $\mu$  alone was not altered by the presence of control cells but was increased two-fold in the presence of BAFF-transfected cells (Fig. 5B). A dose-dependent proliferation of PBL was also obtained when BAFF-transfected cells were replaced by purified sBAFF (Fig. 5C), indicating that BAFF does not require membrane attachment to exert its activity. In this experimental setup, proliferation induced by sCD40L required concentrations exceeding 1  $\mu$ g/ml but was less dependent on the presence of anti- $\mu$  than that mediated by BAFF (Fig. 5D). When purified CD19<sup>+</sup> B cells were co-cultured with irradiated autologous CD19<sup>-</sup> PBL, costimulation of proliferation by BAFF was unaffected, demonstrating that [<sup>3</sup>H]thymidine uptake was mainly due to B cell proliferation and not to an indirect stimulation of another cell type (data not shown). The observed B cell proliferation in response to BAFF was entirely dependent on the presence of anti- $\mu$  antibodies, indicating that BAFF functioned as costimulator of B cell proliferation.

**[0074]** To investigate a possible effect of BAFF on immunoglobulin secretion, purified peripheral or cord blood B cells were preactivated by coculture with EL-4 T cells in the presence of a cytokine mixture from supernatants of PHA/PMA stimulated T cells (23). These B cells were reisolated to 98% purity and yielded a two-fold increase in Ig secretion during a secondary culture in the presence of BAFF and activated T cell cytokines as compared to cytokines alone. A very modest effect occurred in the absence of exogenous cytokines, and an intermediate (1.5-fold) effect was observed in the presence of the recombinant cytokines IL-2, IL-4 and IL-10 (Fig. 5E, F).

**[0075]** The biochemical analysis of BAFF is also consistent with the typical homotrimeric structure of TNF family members. Among this family of ligands, BAFF exhibits the highest level of sequence similarity with APRIL which we have recently characterized as a ligand stimulating growth of various tumor cells (11). Unlike TNF and LT $\alpha$  which are two family members with equally high homology (33% identity) and whose genes are linked on chromosome 6, APRIL and BAFF are not clustered on the same chromosome. APRIL is located on chromosome 17 (J. L. B., unpublished data) whereas BAFF maps to the distal arm of human chromosome 13 (13q34). Abnormalities in this locus were characterized in Burkitt lymphomas as the second most frequent defect (24) besides the translocation involving the myc gene into the Ig locus (25). Considering the high expression levels of BAFF-R on all Burkitt lymphoma cell lines analyzed (see Table 1), this raises the intriguing possibility that some Burkitt lymphomas may have deregulated BAFF expression, thus stimulating growth in an autocrine manner.

**[0076]** The role of antigen-specific B lymphocytes during the different stages of the immune response is highly dependent on signals and contacts from helper T cells and antigen-presenting cells such as dendritic cells (20). B lymphocytes first receive these signals early on during the immune response when they interact with T cells at the edge of the B cell follicles in lymphoid tissues, leading to their proliferation and differentiation into low affinity antibody forming cells (18). At the same time some antigen-specific B cells also migrate to the B cell follicle and contribute to the formation of germinal centers, another site of B cell proliferation but also affinity maturation and generation of memory B cells and high affinity plasma cells (19).

**[0077]** Signals triggered by another member of the TNF super family CD40L have been shown to be critical for the function of B lymphocytes at multiple steps of the T cell-dependent immune response. However, several studies clearly showed that CD40L/CD40 interaction does not account for all contact-dependent T-cell help for B cells. Indeed, CD40L-deficient T cells isolated from either knock-out mice or patients with X-linked hyper IgM syndrome have been shown to successfully induce proliferation of B cells and their differentiation into plasma cells. Studies using blocking antibodies against CD40L showed that a subset of surface IgD positive B cells isolated from human tonsils proliferate and differentiate in response to activated T cells in a CD40-independent manner. Other members of the TNF family such as membrane-bound TNF and CD30L have also been shown to be involved in a CD40- and surface Ig-independent stimulation of B cells. Similar to our results with BAFF, it has been shown that CD40-deficient B cells can be stimulated to proliferate and differentiate into plasma cells by helper T cells as long as the surface Ig receptors are triggered at the same time. BAFF as well as CD30L and CD40L is expressed by T cells but its originality resides in its expression by dendritic cells as well as the highly specific location of its receptor on B cells which is in contrast to CD40, CD30 and the TNF receptor which expression has been described on many different cell. This observation suggests independent and specific BAFF-induced functions on B cells.

**[0078]** In support of a role for BAFF in T cell- and dendritic cell-induced B cell growth and potential maturation, we found that BAFF costimulates proliferation of blood-derived B cells concomitantly with cross-linking of the B cell receptors, and thus, independently of CD40 signalling. Moreover, using CD19 positive B cells differentiated *in vitro* into a pre-plasma cell/ GC-like B cell (14), we observed a costimulatory effect of BAFF on Ig secretion by these B cells in the presence of supernatant from activated T cells or a blend of IL-2, IL-4 and IL-10. Interestingly, the costimulatory effect was stronger in presence of the activated T cell supernatant when compared to the cytokine blend, suggesting

additional soluble factors secreted by activated T cells involved in antibody production which can synergize with BAFF or additional BAFF itself. It is, therefore, possible that BAFF actively contributes to the differentiation of these GC-like B cells into plasma.

[0079] It is clear that BAFF can signal in both naive B cells as well as GC-committed B cells *in vitro*. Whether this observation will translate or not during a normal immune response will have to be addressed by proper *in vivo* experiments.

[0080] The biological responses induced in B cells by BAFF are distinct from that of CD40L, since proliferation triggered by CD40L was less dependent on an anti- $\mu$  costimulus (17) (and Fig. 5D). Moreover, CD40L can counteract apoptotic signals in B cells following engagement of the B cell receptor (29), whereas BAFF was not able to rescue the B cell line Ramos from anti- $\mu$ -mediated apoptosis, despite the fact that Ramos cells do express BAFF-R (Table 1; F. M. and J. L. B., unpublished observations). It is therefore likely that CD40L and BAFF fulfill distinct functions. In this respect, it is noteworthy that BAFF did not interact with any of 16 recombinant receptors of the TNF family tested, including CD40 (P.S. and J.T., unpublished observations).

[0081] B cell growth was efficiently costimulated with recombinant soluble BAFF lacking the transmembrane domain. This activity is in contrast to several TNF family members which are active only as membrane-bound ligand such as TRAIL, FasL and CD40L. Soluble forms of these ligands have poor biological activity which can be enhanced by their cross-linking, thereby mimicking the membrane-bound ligand (15). In contrast, cross-linking Flag-tagged sBAFF with anti-Flag antibodies or the use of membrane-bound BAFF expressed on the surface of epithelial cells did not further enhance the mitogenic activity of BAFF, suggesting that it can act systemically as a secreted cytokine, like TNF does. This is in agreement with the observation that a polybasic sequence present in the stalk of BAFF acted as a substrate for a protease. Similar polybasic sequences are also present at corresponding locations in both APRIL and TWEAK and for both of them there is evidence of proteolytic processing (30) (N.H. and J.T., unpublished observation). Although the protease responsible for the cleavage remains to be determined, it is unlikely to be the metalloproteinase responsible for the release of membrane-bound TNF as their sequence preferences differ completely (21). The multibasic motifs in BAFF (R-N-K-R), APRIL (R-K-R-R) and Tweak (R-P-R-R) are reminiscent of the minimal cleavage signal for furin (R-X-K/R-R), the prototype of a proprotein convertase family (31).

[0082] Practice of the present invention will employ, unless indicated otherwise, conventional techniques of cell biology, cell culture, molecular biology, microbiology, recombinant DNA, protein chemistry, and immunology, which are within the skill of the art. Such techniques are described in the literature. See, for example, **Molecular Cloning: A Laboratory Manual**, 2nd edition. (Sambrook, Fritsch and Maniatis, eds.), Cold Spring Harbor Laboratory Press, 1989; **DNA Cloning**, Volumes I and II (D.N. Glover, ed), 1985; **Oligonucleotide Synthesis**, (M.J. Gait, ed.), 1984; U.S. Patent No. 4,683,195 (Mullis et al.); **Nucleic Acid Hybridization** (B.D. Hames and S.J. Higgins, eds.), 1984; **Transcription and Translation** (B.D. Hames and S.J. Higgins, eds.), 1984; **Culture of Animal Cells** (R.I. Freshney, ed). Alan R. Liss, Inc., 1987; **Immobilized Cells and Enzymes**, IRL Press, 1986; **A Practical Guide to Molecular Cloning** (B. Perbal), 1984; **Methods in Enzymology**, Volumes 154 and 155 (Wu et al., eds), Academic Press, New York; **Gene Transfer Vectors for Mammalian Cells** (J.H. Miller and M.P. Calos, eds.), 1987, Cold Spring Harbor Laboratory; **Immunochemical Methods in Cell and Molecular Biology** (Mayer and Walker, eds.), Academic Press, London, 1987; **Handbook of Experiment Immunology**, Volumes I-IV (D.M. Weir and C.C. Blackwell, eds.), 1986; **Manipulating the Mouse Embryo**, Cold Spring Harbor Laboratory Press, 1986.

[0083] The following Examples are provided to illustrate the present invention, and should not be construed as limiting thereof.

## EXAMPLES

[0084] The following experimental procedures were utilized in Examples 1-6.

### DNA construct for the generation of murine BAFF Tg mice

[0085] Both human and murine cDNA sequences have been described previously (Schneider et al., 1999). A PCR fragment encoding full-length murine BAFF was generated by RT-PCR. First strand cDNA was synthesized from mouse lung polyA+ (Clontech, Palo Alto, CA) using oligo dT according to the manufacturer's protocol (GibcoBRL, Grand Island, NY). The PCR reaction contained 1 x *Pfu* buffer (Stratagene, La Jolla, CA), 0.2 mM dNTPs, 10% DMSO, 12.5 pM primers, 5 units *Pfu* enzyme (Stratagene) and the following primers with NotI restriction sites 5'-TAAGAATGCG-GCCGCGGAATGGATGAGTCTGCAAA-3' and 5'-TAAGAATGCGGCCGCGGGATCACGCACTCCAGCAA-3'. The template was amplified for 30 cycles at 94°C for 1 min, 54 °C for 2 min and 72°C for 3 min followed by a 10 min extension at 72°C. This sequence corresponds to nucleotides 214 to 1171 of the GenBank file AFI 19383. The PCR fragment was digested with NotI and then cloned into a modified pCEP4 vector (Invitrogen, Carlsbad, CA). The fragment containing murine BAFF was removed with XbaI in order to include the SV40 polyA addition site sequence. This frag-

ment was cloned into a pUC based vector where the promoter sequence was added. The promoter, a 1 Kb blunt Bgl2-Not1 fragment containing the human ApoE enhancer and AAT (alpha anti-trypsin) promoter was purified from the plasmid clone 540B (a kind gift from Dr. Katherine Parker Ponder, Washington University, St. Louis, MO). An EcoRV/Bgl2 fragment was purified from the final vector and used for the generation of transgenic mice. The injected offspring of C57BL/6J female x DBA/2J male F1 (BDF1) mice were backcrossed onto C57BL/6 mice. Techniques of microinjection and generation of transgenic mice have been previously described (Mcknights et al., 1983).

#### Analytical Methods:

[0086] Serum samples were subject to reduced SDS-PAGE analysis using a linear 12.5% gel. Total RNA from mouse liver was prepared and processed for Northern Blot analysis using an isolation kit from Promega (Madison, WI) according to the manufacturer's guidelines. BAFF transgene-specific mRNA was detected using a probe spanning the SV40 poly A tail of the transgene construct and obtained by digestion of the modified pCEP4 vector with XbaI and BamHI. The probe recognizes a 1.8-2 Kd band corresponding to mRNA from the BAFF transgene. PCR analysis of tail DNA from BAFF Tg mice was carried using 12.5 pM of the following primers 5'-GCAGTTTCACAGCGATGTCCT-3' [SEQ. ID. NO.: 21] and 5'-GTCTCCGTTGCGTGAAATCTG-3' [SEQ. ID. NO.: 22] in a reaction containing 1X Taq polymerase buffer (Stratagene), 0.2 nM dNTPs, 10% DMSO and 5 units of Taq polymerase (Stratagene). A 719 bp of the transgene was amplified for 35 cycles at 94°C for 30 sec., 54 °C for 1 min. and 72°C for 1.5 min. followed by a 10 min. extension at 72°C.

[0087] The presence of proteins in mouse urine was measured using Multistix 10 SG reagent strips for urinalysis (Bayer Corporation, Diagnostics Division, Elkhart, IN).

#### Cell-dyn and cytofluorimetric analysis (FACS).

[0088] Differential WBC counts of fresh EDTA anticoagulated whole blood were performed with an Abbott Cell Dyne 3500 apparatus (Chicago, IL). For FACS analysis, Fluorescein (PTTC)-, Cy-chrome- and Phycoerythrin- (PE)-labeled rat anti-mouse antibodies: anti-B220, anti-CD4, anti-CD8, anti-CD43, anti-IgM, anti-CD5, anti-CD25, anti-CD24, anti-CD38, anti-CD21, anti-CD44, anti-L-selectin and hamster anti-Bcl-2/control hamster Ig kit were purchased from Pharmingen (San Diego, CA). Production of recombinant E. coli as well as mammalian cell-derived human and mouse Flag-tagged BAFF were previously described (Schneider et al., 1999). All antibodies were used according to the manufacturer's specifications. PBL were purified from mouse blood as follows: mouse blood was collected in microtubes containing EDTA and was diluted 1/2 with PBS. Five hundred µl of diluted blood was applied on top of 1 ml of ficoll (Celardane, Homby, Ontario, Canada) in a 4 ml glass tube, the gradient was performed at 2000 rpm for 30 min at room temperature and the interface containing the lymphocytes was collected and washed twice in PBS prior to FACS staining. Spleen, bone marrow and mesenteric lymph nodes were ground into a single cell suspension in RPMI medium (Life Technologies, Inc., Grand Island, NY) and washed in FACS buffer (PBS supplemented with 2% fetal calf serum (JRH Biosciences, Lenexa, KS). Cells were first suspended in FACS buffer supplemented with the following blocking reagents: 10 µg/ml human Ig (Sandoz, Basel, Switzerland) and 10 µg/ml anti-mouse Fc blocking antibody (Pharmingen) and incubated 30 min on ice prior to staining with fluorochrome-labeled antibodies. All antibodies were diluted in FACS buffer with the blocking reagent mentioned above. Samples were analyzed using a FACScan cytofluorometer (Becton Dickinson).

#### Detection of total mouse Ig and rheumatoid factors in mouse sera by ELISA assays.

[0089] ELISA plates (Corning glass works, Corning, NY) were coated overnight at 4°C with a solution of 10 µg/ml of goat anti-total mouse Ig (Southern Biotechnology Associates, Inc. Birmingham, AL) in 50 mM sodium bicarbonate buffer pH 9.6. Plates were washed 3 times with PBS/0.1% Tween and blocked overnight with 1% gelatin in PBS. One hundred µl/well of serum serial dilutions or standard dilutions was added to the plates for 30 min at 37°C. Mouse Ig were detected using 100 µl/well of a 1 µg/ml solution of an Alkaline Phosphatase (AP)-labeled goat anti-total mouse Ig (Southern Biotechnology Associates) for 30 min at 37 °C. After a last wash, 3 times with PBS/0.1% Tween, the enzymatic reaction was developed using a solution of 10µg/ml of p-nitrophenyl phosphate (Boehringer Mannheim, Indianapolis, IN) in 10% diethanolamine. The reaction was stopped by adding 100 µl of 3N NaOH/well. The optical density (O.D.) was measured at 405 nm using a spectrophotometer from Molecular Devices (Sunnyvale, CA). Standard curves were obtained using purified mouse Ig purchased from Southern Biotechnology Associates. In the case of detection of rheumatoid factors (RF), the plates were coated with normal goat Ig (Jackson ImmunoResearch laboratories, Inc., West Grove, PA) instead of goat anti-mouse Ig and detection of mouse Ig was performed as described above. Detection of mouse isotypes in the RF assay was done using AP-labeled goat anti-mouse IgA, IgM, IgG2a, IgG2b and IgG3, as well as purified mouse IgA, IgM, IgG2a, IgG2b and IgG3 for standard curves (Southern Biotech-



nology Associates Inc.). All statistical comparisons were performed by analysis of variance.

#### Detection of circulating immune complexes (CIC) and precipitation of cryoglobulins in mouse sera.

5 **[0090]** The assay was performed as previously described (June et al., 1979; Singh and Tingle, 1982) with the following modifications: ELISA plates (Corning glass works) were coated overnight at 4°C with 5 µg/ml of human C1q (Quidel, San Diego, CA) in 50 mM sodium bicarbonate buffer pH 9.6. The plates were washed 3 times with PBS/0.1% Tween. Fifty µl/well of 0.3 M EDTA was added to the plates plus 50 µl/well of serum serial dilutions or solutions of known concentrations of a standard immune complex (peroxidase-mouse anti-peroxidase (PAP) from DAKO (Carpinteria, CA). The plates were incubated 30 min at 37 °C. The plates were washed 3 times with PBS/0.1% Tween. Mouse Ig in the immune complexes were detected using 100 µl/well of a 1 µg/ml solution of an AP-labeled goat anti-mouse Ig (Southern Biotechnology Associates, Inc.) as described above for the ELISA assays. Cryoglobulins were detected by incubating overnight at 4°C mouse serum diluted 1/15 in water and precipitates were scored visually.

#### 15 Anti-double stranded (ds) and single stranded (ss) DNA assays.

**[0091]** Anti-ssDNA were performed using NUNC-immuno Plate MaxiSorp plates (NUNC A/S, Denmark). Plates were coated overnight at 4°C first with 100 µg/ml methylated BSA (Calbiochem Corp., La Jolla, CA), then with 50 µg/ml grade [calf thymus DNA (Sigma, St. Louis, MO). The calf thymus DNA was sheared by sonication and then digested with S1 nuclease before use. For the anti-ssDNA assay, the DNA was boiled for 10 min and chilled on ice before use. After blocking, serial dilutions of the serum samples were added and incubated at room temperature for 2 h. Autoantibodies were detected with goat anti-mouse IgG-AP (Sigma) and develop as described above for the ELISA assays. Standard curves were obtained using known quantities of anti-DNA mAb 205, which is specific for both ss- and dsDNA (Datta et al., 1987).

25

#### Immunohistochemistry

**[0092]** Spleen and lymph nodes were frozen in O.C.T. embedding medium (Miles, Elkhart, IN) and mounted for cryostat sectioning. Sections 7-10 µm thick were dried and fixed in acetone. All Ab incubations (10 µg/ml) were done for 1 hr at room temperature in a humidified box after dilution in Tris-buffered saline A (TBS-A, 0.05M Tris, 0.15M NaCl, 0.05% Tween-20 (v/v), 0.25% BSA), rinsed in TBS-B (0.05M Tris, 0.15M NaCl, 0.05% Tween-20) and fixed 1 min in methanol before initiating the enzymatic reaction. Horseradish peroxidase (HRP) and alkaline phosphatase (AP) activities were developed using the diaminobenzidine (DAB) tablet substrate kit (Sigma) and the 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT, Pierce, Rockford, IL), respectively. Stained tissue sections were finally fixed 5 min in methanol and counter stained with Giemsa (Fluka, Buchs, Switzerland). Biotin-labeled antibodies rat anti-B220, anti-CD11c, anti-syndecan-1 as well as unlabeled rat anti-CD4, anti-CD8α and anti-CD8β were purchased from Pharmingen. Biotin-labeled peanut agglutinin (PNA) was obtained from Vector laboratories (Burlingame, CA). (HRP)-labeled mouse anti-rat Ig and (HRP)-streptavidin were purchased from Jackson ImmunoResearch laboratories, Inc. and AP-labeled streptavidin from Southern Biotechnology Associates, Inc. In the case of immunohistochemistry on kidney tissue to detect Ig deposition, paraffin section were used, dewaxed and blocked using diluted horse serum from Vector (Burlingame, CA), followed by staining with HRP-goat anti-mouse Ig from Jackson Immunoresearch. Detection was performed as described above.

45

#### Example 1

##### BAFF transgenic (BAFF Tg) founder mice have an abnormal phenotype.

**[0093]** Full length murine BAFF was expressed in transgenic mice using the liver specific alpha-1 antitrypsin promoter with the APO E enhancer. The full length version was chosen with the expectation that BAFF would be either cleaved and act systemically or if retained in a membrane bound form that local liver specific abnormalities would be observed possibly providing functional clues. We obtained 13 founder mice positive for the BAFF transgene (Table 2). Four of these mice died at a young age. Routine pathology was carried out on mice 811 and 816 (Table 2). There was no obvious infection in these mice; however, cardiovascular and renal abnormalities were apparent and similar to those described for severe hypertension (Fu, 1995) (Table 2). Hematoxylin and eosin (H&E)-stained kidney tissue sections of founder 816 showed that the morphology of glomeruli in that mouse was abnormal, whereas the rest of the kidney tissue seemed normal (data not shown). Many BAFF transgenic founder mice had proteinuria (Table 2). Immunohistochemistry on spleen frozen tissue sections from mouse 816, revealed an abnormal and extensive B cell staining and reduced staining for T cells and this observation was confirmed in the progeny (see below, Figure 12).

[0094] Using two color FACS analysis, the ratio of % B220 positive B cells over % CD4 positive T cells was calculated. This ratio was two to seven times higher in BAFF Tg founder mice when compared to control negative BDF1 mice (Table 2), suggesting an increase of the B cell population in BAFF Tg mice. We selected nine of these founder mice to generate our different lines of transgenic mice as underlined in Table 2. None of the remaining BAFF Tg founder mice or the derived progeny showed any signs of ill health months after the early death of founders 696, 700, 811 and 816, suggesting that these 4 mice might have expressed higher levels of BAFF which caused their death. BAFF over-expression in the liver of transgenic mice was confirmed by Northern blot analysis (data not shown). In all BAFF-Tg mice examined histologically, the livers showed no abnormalities indicating that local overexpression of BAFF did not induce any immunological or pathological events. An ELISA assay for murine BAFF is not available; however, we showed that 2% serum from BAFF Tg mice, but not from control mice, blocked the binding of mammalian cell-derived mouse soluble Flag-tagged BAFF to BJAB cells. Moreover, 5% serum from BAFF Tg mice but not from control mice increased the proliferation of human B cells from PBL in the presence of anti- $\mu$  (data not shown). These data suggest that substantial amounts of soluble BAFF are present in the blood of BAFF Tg.

## Example 2

### Peripheral lymphocytosis in BAFF Tg mice is due to elevated B cell numbers

[0095] The transgenic mice population was found to have more lymphocytes in the blood when compared to control negative littermates, reaching values as high as 13000 lymphocytes/ $\mu$ l of blood (Figure 7A). In contrast, the number of granulocytes per  $\mu$ l of blood in both BAFF Tg mice and control mice remained within normal limits (Figure 7A). Since FACS analysis, using anti-CD4 and anti-B220 antibodies, of peripheral blood cells (PBL) from 18 BAFF Tg mice issued from six different founder mice showed increased B/T ratios (Figure 7B and 7C), the elevated lymphocyte levels resulted from an expanded B cell subset. Likewise, using this method, calculation of absolute numbers of CD4 circulating T cells revealed a 50% reduction of this T cell subset in BAFF Tg mice when compared to control mice, and the same observation was made for the CD8 T cell subset (data not shown). All B cells from the PBL of BAFF Tg mice have increased MHC class II and Bcl-2 expression when compared to B cells from control mice (Figure 7D and 7E, respectively), indicating some level of B cell activation in PBL of BAFF Tg mice. T cells in the blood of BAFF Tg mice did not express the early activation markers CD69 or CD25; however, 40 to 56% of CD4 or CD8 T cells were activated effector T cells with a CD44<sup>hi</sup>, L-selectin<sup>lo</sup> phenotype versus only 8% to 12% in control littermates (Figure 7F). Thus BAFF Tg mice clearly show signs of B cell lymphocytosis and global B cell activation along with T cell alterations.

## Example 3

### Expanded B cell compartments are composed of mature cells.

[0096] To see whether overexpression of BAFF in the transgenic mice was affecting the B cell compartment centrally in the bone marrow and peripherally in secondary lymphoid organs, we examined by FACS the spleen, bone marrow and mesenteric lymph nodes from a total of seven BAFF Tg mice and seven control littermates derived from four different founder mice. The mature B cell compartment was analyzed by staining with both anti-B220 and anti-IgM antibodies. Two representative BAFF Tg mice and one representative control littermate are shown in Figure 8. The mature B cell compartment (IgM<sup>+</sup>, B220<sup>+</sup>) was increased in both the spleen and the mesenteric lymph nodes (Figure 8A, top and bottom panels, respectively). Analysis of B220<sup>+</sup>/IgM<sup>+</sup> B cells (Figure 7A, middle panel) or the proB cell (CD43<sup>+</sup>/B220<sup>+</sup>) and the preB cell (CD43<sup>-</sup>/B220<sup>+</sup>) compartments in the bone marrow (Figure 8B) showed that BAFF Tg mice and control littermates were similar. These data indicate that overexpression of BAFF is affecting the proliferation of mature B cells in the periphery but not progenitor B cells in the bone marrow. Analysis by FACS of the B cell subpopulations in the spleen, revealed an increased proportion of marginal zone (MZ) B cells in BAFF Tg mice when compared to control mice (Table 3). The population of follicular B cells remained proportional in both BAFF Tg and control mice whereas the fraction of newly formed B cells is slightly decreased in BAFF Tg mice (Table 3). This result was also confirmed on B220<sup>+</sup> splenic B cells using anti-CD38 versus anti-CD24 antibodies and anti-IgM versus anti-IgD antibodies and analyzing for at the CD38<sup>hi</sup>/CD24<sup>+</sup> and IgM<sup>hi</sup>/IgD<sup>lo</sup> for the MZ B cell population, respectively, as previously described (Oliver et al., 1997)(data not shown). Immunohistochemical analysis using an anti-mouse IgM antibody revealed the expansion of the IgM-bright MZ B cell area in the spleen of BAFF Tg mice when compared to control mice (data not shown). All BAFF Tg B220<sup>+</sup> splenic B cells also express higher levels of MHC class II (Table 3) and Bcl-2 (data not shown) compared to splenic B cells from control mice, indicating that splenic B cells as well as B cells from PBL are in an activated state.

**Example 4**

**BAFF Tg mice have high levels of total immunoglobulins, rheumatoid factors and circulating immune complexes in their serum.**

[0097] The increased B cell compartment in BAFF Tg mice suggested that the level of total Ig in the blood of these animals might also be increased. SDS-PAGE, analysis of serum from BAFF Tg mice and control littermates showed that the heavy and light chains IgG bands were at least 10 fold more intense in 3 out of 4 BAFF Tg mice compared to the control sera (Figure 9A). Likewise, an ELISA determination on the sera from BAFF Tg mice show significantly higher total Ig levels when compared to that of the control mice (Figure 9B).

[0098] Despite the high levels seen by SDS-PAGE, the excessively high levels of Ig seen by ELISA determination in some mice, e.g., 697-5, 816-8-3 and 823-20, led us to suspect the presence of rheumatoid factors (RF) in the sera, or autoantibodies directed against antigenic determinants on the Fc fragment of IgG (Jefferis, 1995). These antibodies could bind to the goat anti-mouse Ig used to coat the ELISA plates and give erroneously high values. ELISA plates were coated with normal irrelevant goat Ig and the binding of BAFF Tg Ig to normal goat Ig was measured. Figure 9C shows that sera from most BAFF Tg mice contained Ig reacting with normal goat Ig, whereas only two out of 19 control mice exhibited reactivity in the same assay. These RF were mainly of the IgM, IgA and IgG2a isotypes (data not shown).

[0099] Presence of RF can be associated with the presence of high levels of circulating immune complexes (CIC) and cryoglobulin in the blood (Jefferis, 1995). To verify whether or not BAFF Tg mice have abnormal serum levels of CIC, a C1q-based binding assay was used to detect CIC in the 21 BAFF Tg mice analyzed above. Only 5 BAFF Tg showed significantly high levels of CIC when compared to control mice, nonetheless these mice corresponded to the animals having the highest total Ig and rheumatoid factor levels (Figure 9D). We also observed precipitate formation when BAFF Tg mice sera were diluted 1/15 in water but not control sera indicating the presence of cryoglobulin in these mice (data not shown). Thus, in addition to B cell hyperplasia, BAFF Tg mice display severe hyperglobulinemia associated with RF and CIC.

**Example 5**

**Some BAFF Tg mice have high levels of anti-single stranded (ss) and double-stranded (ds) DNA autoantibodies.**

[0100] Initially, we observed kidney abnormalities reminiscent of a lupus-like disease in two of our founder mice (Table II). The presence of anti-DNA autoantibodies have also been described in SLE patients or the SLE-like (SWR x NZB)F1 (SNF1) mouse (Datta et al., 1987). Anti-ssDNA autoantibody levels were detected in BAFF Tg mice previously shown to have the highest level of total serum Ig (Figure 10A). We analyzed the serum of two BAFF Tg mice negative for antibodies against ssDNA (697-5 and 816-1-1) and three transgenic mice secreting anti-ssDNA antibodies (820-14, 816-8-3 and 820-7) for the presence of anti-dsDNA antibodies in parallel with five control littermates. BAFF Tg mice also secreted anti-dsDNA, however, the levels of secretion did not always correlate with that of anti-ssDNA antibodies, as serum from BAFF Tg mouse 697-5 which did not contain detectable levels of anti-ssDNA antibodies, was clearly positive for the presence of anti-dsDNA (Figure 10B). Therefore, BAFF Tg mice showing the most severe hyperglobulinemia secrete pathological levels of anti-DNA autoantibodies. Additionally, and also reminiscent of a lupus-like problem in these mice we detected immunoglobulin deposition in the kidney of six BAFF Tg mice analyzed (Figure 10C), three of these mice did not secrete detectable levels anti-DNA antibodies (data not shown).

**Example 6**

**BAFF Tg mice have enlarged B cell follicles, numerous germinal centers, reduced dendritic cell numbers and increased plasma cell numbers in both the spleen and mesenteric lymph nodes (MLN).**

[0101] BAFF Tg mice had large spleens, MLN (data not shown) and Peyer's patches (Figure 11). Immunohistochemistry showed the presence of enlarged B cell follicles and reduced peripheral arteriolar lymphoid sheets (PALS or T cell area) in BAFF Tg mice (Figure 12B). Interestingly, few germinal centers were observed in non-immunized control littermates (and is typical of this colony in general) and those present were small (Figure 12C), whereas BAFF Tg mice possessed numerous germinal centers in the absence of immunization (Figure 12D). Staining with anti-CD11c for dendritic cells in the T cell zone and the marginal zone of control mice (Figure 12E) was considerably reduced in BAFF Tg mice (Figure 12F). Syndecan-1-positive plasma cells were almost undetectable in the spleen from control littermates (Figure 12G), yet the red pulp of BAFF Tg mice was strongly positive for syndecan-1 (Figure 12H). Very similar observations were made for the MLN (Figure 13). In the MLN of BAFF Tg mice the B cell areas were dramatically expanded (Figure 13B) in contrast to the normal node where B cell follicles were easily recognizable at the periphery

of the node under the capsule with a typical paracortical T cell zone (Figure 13A). The medulla of MLN from BAFF Tg mice were filled with syndecan-1 positive cells which presumably are plasma cells (Figure 13H). In conclusion, analysis of secondary lymphoid organs in BAFF Tg mice was consistent with the expanded B cell phenotype showing multiple cellular abnormalities and intense immune activity.

## References

[0102]

1. Smith et al. (1994) *Cell* 76:959-962.
2. Vassalli (1992) *Annu. Rev. Immunol.* 10:411-452.
3. De Togni et al. (1994) *Science* 264:703-707.
4. Koni et al. (1997) *Immunity* 6:491-500.
5. Amakawa et al. (1996) *Cell* 84:551-562.
6. Russell et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:4409-4413.
7. Zheng et al. (1995) *Nature* 377:348-351.
8. van Kooten and Banchereau (1997) *Curr. Opin. Immunol.* 9:330-337.
9. Stuber and Strober (1996). *J. Exp. Med.* 183:979-989.
10. Schneider et al. (1997) *J. Biol. Chem.* 272:18827-18833.
11. Hahne et al. (1998) *J. Exp. Med.* 188:1185-1190.
12. Hahne et al. (1996) *Science* 274:1363-1366.
13. Grimaire et al. (1997) *Eur. J. Immunol.* 27:199-205.
14. Thome et al. (1997) *Nature* 386:517-521.
15. Schneider et al. (1998) *J. Exp. Med.* 187:1205-1213.
16. Matsudaira, P. (1987) *J. Biol. Chem.* 262:10035-10038.
17. Armitage et al. (1992) *Nature* 357:80-82.
18. Bucher et al. (1996) *Computer Chem.* 20:3-24.
19. Banner et al. (1993) *Cell* 73:431-445.
20. Nagata (1997) *Cell* 88:355-365.
21. Black et al. (1997) *Nature* 385:729-733.
22. Wong et al. (1997) *J. Biol. Chem.* 272:25190-25194.
23. Kindler and Zubler, (1997) *J. Immunol.* 159:2085-2090.
24. Sonoki et al. (1995) *Leukemia* 9:2093-2099.
25. Magrath, I. (1990) *Adv Cancer Res* 55:133-270.

26. Garside et al. (1998) *Science* 281:96-99.

27. MacLennan et al. (1997) *Immunol. Rev.* 156:53-66.

28. Dubois et al. (1997). *J. Exp. Med.* 185:941-951.

29. Tsubata et al. (1993) *Nature* 364:645-648.

30. Chicheportiche et al. (1997) *J. Biol. Chem.* 272:32401-32410.

31. Nakayama (1997) *Biochem. J.* 327:625-635.

32. Jefferis, R. (1995). Rheumatoid factors, B cells and immunoglobulin genes. *Br. Med. Bull.* 51, 312-331.

33. Schneider et al. (1999) *J. Exp. Med.* 189, 1747-1756.

34. Mcknights et al. (1983) *Cell* 34, 335-341.

35. Datta et al. (1987) *J. Exp. Med.* 165, 1252-1261.

Table I:

Expression of MARCH-R in different cell lines			
Cell type	Cell lines	MARCH binding	Specific details
Epithelial-like	HT-29	-	colon adenocarcinoma
	A375	-/+	melanoma
	MCF-7	-	breast adenocarcinoma.
	ME260	-	melanoma
	Cos	+	monkey kidney cells
Fibroblasts	WI-38	-	lung
	Hs-68	-	foreskin
	Hs-27	-	foreskin
Endothelial cells	HUVEC	-	umbilical vein
Macrophages/ monocytes	THP-1	-/+	monocyte
T cell lines	Molt-4	-	lymphoblastic leukemia
	Hut-78	-	cutaneous lymphoma
	Jurkat	-	lymphoblastic leukemia
B cell lines	BJAB	+++	Burkitt lymphoma
	Namalawa	++	Burkitt lymphoma
	Daudi	+/-	Burkitt lymphoma EBNA+ VCA+
	Ramos	++	Burkitt lymphoma EBV-
	Raji	+++	Burkitt lymphoma
	JIYOYE	+	Burkitt lymphoma
	SKW.64	++	IgM secreting EBV+
	RPMI 1788	+++	peripheral blood, IgM secreting
	IM-9	+++	lymphoblast Ig secreting
	NC-37	+++	lymphoblast EBV+
Mouse cell lines	WEHI-231	-	B cell lymphoma
	A20	-	B cell lymphoma
Surface expression of MARCH was determined by FACS using FLAG-tagged MARCH as described in Material and Methods			

Table II.

Table II. .t of BAFF transgenic founder mice		
Mouse number	Proteinuria <sup>a</sup>	B/T <sup>b</sup>
690 female <sup>d</sup>	ND	2
696 male <sup>c</sup>	ND	ND
697 female	+++	ND
700 male <sup>c</sup>	ND	ND
802 male	++	4.6
804 female	+++	5.4
807 female	ND	4
810 male	+++	7.8
811 male <sup>c/e</sup>	ND	ND
813 male	+	5.4
816 female <sup>e/f</sup>	++	ND
820 male	++	3
823 male	++	2.9
Control BDF1 female	+/-	1.5
Control BDF1 male	+/-	2.5

<sup>a</sup> Proteinuria was measured using medical color strips dipped in mouse urine and is defined as follows: - no proteinuria, +/- trace, + (30 mg/dl), ++ (100 mg/dl), +++ (300 mg/dl), ++++ (>2000 mg/dl).

<sup>b</sup> B/T: is the ration of % B cells over % T cells in PBL as determined by FACS analysis, using PE-labeled anti-B220 and FTTC-labeled anti-CD4 antibodies for double staining.

<sup>c</sup> Early acute death

<sup>d</sup> No transgene transmission in progeny.

<sup>e</sup> Cardiovascular and renal abnormalities observed during autopsy.

<sup>f</sup> Mouse sacrificed due to presence of blood in urine. Heart, Kidney and arteries abnormalities were apparent after analysis of H&E-stained sections from all tissues, increased splenic B cell population as determined by immunohistochemistry on spleen frozen sections using biotin-labeled anti-mouse B220 and anti-mouse CD4, followed by alkaline phosphatase-labeled streptavidin and horseradish peroxidase-labeled anti-rat Ig.

Underlined founder mice used for breeding

ND: not done

**Table 3: Increased MHC class II expression on B cells and enlarged proportion of MZ B cells in the spleen of BAFF Tg mice.**

	Level s of MHC class II expression on B220 <sup>+</sup> B cells (MFI)	% of follicular B cells (B220 <sup>+</sup> /IgM <sup>b</sup> /CD21 <sup>hi</sup> )	% of MZ B cells (B220 <sup>+</sup> /IgM <sup>hi</sup> /CD21 <sup>hi</sup> )	% of newly formed B cells (B220 <sup>+</sup> /IgM <sup>hi</sup> /CD21 <sup>hi</sup> )
<b><u>Control mice</u></b>				
816-1-10	1170	45	6	12
802-21	1029	48	10.5	9
823-1	1240	39	9	6.5
<b><u>Baff Tg mice</u></b>				
802-6	1707	49	18	5.9
820-7	1900	39	23	6.3
816-1-1	2088	40	23	5.8

Splenocytes were analysed by FACS and gated on the B220<sup>+</sup> population.  
 A representative experiment is shown.  
 MFI: mean of fluorescence intensity

**Claims**

1. Use of a composition selected from the group consisting of:

- (a) BAFF (B cell activating factor belonging to the TNF family) or an active fragment thereof;
- (b) BAFF or an active fragment thereof and an anti- $\mu$  antibody;
- (c) BAFF or an active fragment thereof and CD40 ligand; and
- (d) BAFF or an active fragment thereof and a monoclonal anti-CD40 ligand antibody

5

for the preparation of a pharmaceutical composition for stimulating B-cell growth.

2. Use of a composition selected from the group consisting of:

10

- (a) BAFF or an active fragment thereof;
- (b) BAFF or an active fragment thereof and an anti- $\mu$  antibody;
- (c) BAFF or an active fragment thereof and CD40 ligand; and
- (d) BAFF or an active fragment thereof and a monoclonal anti-CD40 ligand antibody

15

for the preparation of a pharmaceutical composition for stimulating immunoglobulin production.

3. Use of a composition selected from the group consisting of:

20

- (a) BAFF or an active fragment thereof;
- (b) BAFF or an active fragment thereof and an anti- $\mu$  antibody;
- (c) BAFF or an active fragment thereof and CD40 ligand; and
- (d) BAFF or an active fragment thereof and a monoclonal anti-CD40 ligand antibody

25

for the preparation of a pharmaceutical composition for co-stimulating B-cell growth and immunoglobulin production.

4. Use of a composition selected from the group consisting of:

30

- (a) BAFF or an active fragment thereof;
- (b) BAFF or an active fragment thereof and an anti- $\mu$  antibody;
- (c) BAFF or an active fragment thereof and CD40 ligand; and
- (d) BAFF or an active fragment thereof and a monoclonal anti-CD40 ligand antibody

35

for the preparation of a pharmaceutical composition for stimulating dendritic cell-induced B-cell growth and maturation.

5. Use of a composition comprising an antibody specific for BAFF or an active fragment thereof, or an antibody specific for BAFF receptor or an epitope thereof for the preparation of a pharmaceutical composition for inhibiting B-cell growth.

40

6. Use of a composition comprising an antibody specific for BAFF or an active fragment thereof, or an antibody specific for BAFF receptor or an epitope thereof for the preparation of a pharmaceutical composition for inhibiting immunoglobulin production.

45

7. Use of a composition comprising an antibody specific for BAFF or an active fragment thereof, or an antibody specific for BAFF receptor or an epitope thereof for the preparation of a pharmaceutical composition for co-inhibiting B-cell growth and immunoglobulin production.

50

8. Use of a composition comprising an antibody specific for BAFF or an active fragment thereof, or an antibody specific for BAFF receptor or an epitope thereof for the preparation of a pharmaceutical composition for inhibiting dendritic cell-induced B-cell growth and maturation.

9. Use of an antibody specific for BAFF or an active fragment thereof, or an antibody specific for BAFF receptor or an epitope thereof for the preparation of a pharmaceutical composition for treating hypertension.

55

10. Use of a composition selected from the group consisting of:

- (a) BAFF or an active fragment thereof;



- (b) BAFF or an active fragment thereof and an anti- $\mu$  antibody;
- (c) BAFF or an active fragment thereof and CD40 ligand;
- (d) BAFF or an active fragment thereof and a monoclonal anti-CD40 ligand antibody;
- (e) an antibody specific for BAFF or an active fragment thereof; and
- (f) an antibody specific for BAFF receptor or an epitope thereof

for the preparation of a pharmaceutical composition for the treatment of an autoimmune disease.

11. The use according to any one of claims 1 to 4 and 10, wherein the BAFF is a soluble BAFF.

12. The use according to claim 11, wherein the soluble BAFF is a recombinant BAFF.

13. The use according to any one of claims 5 to 10, wherein the anti-BAFF antibody or the anti-BAFF receptor antibody is a monoclonal antibody.

14. Use of an antibody specific for BAFF or an active fragment thereof, or an antibody specific for a BAFF receptor or an epitope thereof for the preparation of a pharmaceutical composition for inhibiting inflammation.

15. Use of BAFF or an active fragment thereof for the preparation of a pharmaceutical composition for regulating hematopoietic cell development.

16. Use of a composition selected from the group consisting of:

- (a) BAFF or an active fragment thereof;
- (b) BAFF or an active fragment thereof and an anti- $\mu$  antibody;
- (c) BAFF or an active fragment thereof and CD40 ligand;
- (d) BAFF or an active fragment thereof and a monoclonal anti-CD40 ligand antibody;
- (e) an antibody specific for BAFF or an active fragment thereof; and
- (f) an antibody specific for BAFF receptor or an epitope thereof

for the preparation of a pharmaceutical composition for stimulating B-cell production in the treatment of immunosuppressive diseases.

17. The use according to claim 16, wherein the immunosuppressive disease is HIV or associated with an organ transplantation.

## Patentansprüche

1. Verwendung einer Zusammensetzung ausgewählt aus der Gruppe bestehend aus:

- (a) BAFF (B-Zelle aktivierender Faktor, der zur TNF-Familie gehört) oder einem aktiven Fragment davon;
- (b) BAFF oder einem aktiven Fragment davon und einem anti- $\mu$ -Antikörper;
- (c) BAFF oder einem aktiven Fragment davon und einem CD40-Liganden; und
- (d) BAFF oder einem aktiven Fragment davon und einem monoclonalen anti-CD40-Ligand-Antikörper

für die Herstellung eines Arzneimittels zur Stimulation des B-Zellenwachstums.

2. Verwendung einer Zusammensetzung ausgewählt aus der Gruppe bestehend aus:

- (a) BAFF oder einem aktiven Fragment davon;
- (b) BAFF oder einem aktiven Fragment davon und einem anti- $\mu$ -Antikörper;
- (c) BAFF oder einem aktiven Fragment davon und einem CD40-Liganden; und
- (d) BAFF oder einem aktiven Fragment davon und einem monoclonalen anti-CD40-Ligand-Antikörper

für die Herstellung eines Arzneimittels zur Stimulation der Immunglobulinproduktion.

3. Verwendung einer Zusammensetzung ausgewählt aus der Gruppe bestehend aus:

- (a) BAFF oder einem aktiven Fragment davon;
- (b) BAFF oder einem aktiven Fragment davon und einem anti- $\mu$ -Antikörper;
- (c) BAFF oder einem aktiven Fragment davon und einem CD40-Liganden; und
- (d) BAFF oder einem aktiven Fragment davon und einem monoclonalen anti-CD40-Ligand-Antikörper

5

für die Herstellung eines Arzneimittels zur Co-Stimulation des B-Zellenwachstums und der Immunglobulinproduktion.

4. Verwendung einer Zusammensetzung ausgewählt aus der Gruppe bestehend aus:

10

- (a) BAFF oder einem aktiven Fragment davon;
- (b) BAFF oder einem aktiven Fragment davon und einem anti- $\mu$ -Antikörper;
- (c) BAFF oder einem aktiven Fragment davon und einem CD40-Liganden; und
- (d) BAFF oder einem aktiven Fragment davon und einem monoclonalen anti-CD40-Ligand-Antikörper

15

für die Herstellung eines Arzneimittels zur Stimulation des/der von dendritischen Zellen induzierten B-Zellenwachstums und -Reifung.

5. Verwendung einer Zusammensetzung, umfassend einen BAFF-spezifischen Antikörper oder ein aktives Fragment davon, oder einen BAFF-Rezeptor-spezifischen Antikörper oder ein Epitop davon für die Herstellung eines Arzneimittels zur Hemmung des B-Zellenwachstums.

20

6. Verwendung einer Zusammensetzung, umfassend einen BAFF-spezifischen Antikörper oder ein aktives Fragment davon, oder einen BAFF-Rezeptor-spezifischen Antikörper oder ein Epitop davon für die Herstellung eines Arzneimittels zur Hemmung der Immunglobulinproduktion.

25

7. Verwendung einer Zusammensetzung, umfassend einen BAFF-spezifischen Antikörper oder ein aktives Fragment davon, oder einen BAFF-Rezeptor-spezifischen Antikörper oder ein Epitop davon für die Herstellung eines Arzneimittels zur Co-Hemmung des B-Zellenwachstums und der Immunglobulinproduktion.

30

8. Verwendung einer Zusammensetzung, umfassend einen BAFF-spezifischen Antikörper oder ein aktives Fragment davon, oder einen BAFF-Rezeptor-spezifischen Antikörper oder ein Epitop davon für die Herstellung eines Arzneimittels zur Hemmung des/der von dendritischen Zellen induzierten B-Zellenwachstums und -Reifung.

35

9. Verwendung eines BAFF-spezifischen Antikörpers oder einem aktiven Fragment davon oder eines BAFF-Rezeptor-spezifischen Antikörpers oder eines Epitops davon für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck.

10. Verwendung einer Zusammensetzung ausgewählt aus der Gruppe bestehend aus:

40

- (a) BAFF oder einem aktiven Fragment davon;
- (b) BAFF oder einem aktiven Fragment davon und einem anti- $\mu$ -Antikörper;
- (c) BAFF oder einem aktiven Fragment davon und einem CD40-Liganden;
- (d) BAFF oder einem aktiven Fragment davon und einem monoclonalen anti-CD40-Ligand-Antikörper;
- (e) einem BAFF-spezifischen Antikörper oder einem aktiven Fragment davon; und
- (f) einem BAFF-Rezeptor-spezifischen Antikörper oder einem Epitop davon

45

für die Herstellung eines Arzneimittels zur Behandlung einer Autoimmunerkrankung.

50

11. Verwendung nach einem der Ansprüche 1 bis 4 und 10, wobei der BAFF ein löslicher BAFF ist.

12. Verwendung nach Anspruch 11, wobei der lösliche BAFF ein rekombinanter BAFF ist.

55

13. Verwendung nach einem der Ansprüche 5 bis 10, wobei der anti-BAFF-Antikörper oder der anti-BAFF-Rezeptorantikörper ein monoclonaler Antikörper ist.

14. Verwendung eines BAFF-spezifischen Antikörpers oder eines Fragments davon oder eines BAFF-Rezeptor-spezifischen Antikörpers oder eines Epitops davon für die Herstellung eines Arzneimittels zur Hemmung von Entzündungen.

dungen.

15. Verwendung von BAFF oder eines aktiven Fragments davon für die Herstellung eines Arzneimittels zur Regulierung der Entwicklung blutbildender Zellen.

16. Verwendung einer Zusammensetzung ausgewählt aus der Gruppe bestehend aus:

- (a) BAFF oder einem aktiven Fragment davon;
- (b) BAFF oder einem aktiven Fragment davon und einem anti- $\mu$ -Antikörper;
- (c) BAFF oder einem aktiven Fragment davon und einem CD40-Liganden;
- (d) BAFF oder einem aktiven Fragment davon und einem monoclonalen anti-CD40-Ligand-Antikörper;
- (e) einem BAFF-spezifischen Antikörper oder einem aktiven Fragment davon; und
- (f) einem BAFF-Rezeptor-spezifischen Antikörper oder einem Epitop davon

für die Herstellung eines Arzneimittels zur Stimulation der B-Zellenproduktion zur Behandlung von immunsuppressiven Erkrankungen.

17. Verwendung nach Anspruch 16, wobei die immunsuppressive Erkrankung HIV oder eine mit Organtransplantation assoziierte Erkrankung ist.

#### Revendications

1. Utilisation d'une composition sélectionnée dans le groupe consistant en :

- (a) FABF (Facteur d'activation des cellules B appartenant à la famille de TNF) ou son fragment actif;
- (b) FABF ou son fragment actif et un anticorps anti- $\mu$ ;
- (c) FABF ou son fragment actif et un ligand de CD40 ; et
- (d) FABF ou son fragment actif et un anticorps monoclonal anti-ligand de CD40

pour la préparation d'une composition pharmaceutique pour stimuler la croissance des cellules B.

2. Utilisation d'une composition sélectionnée dans le groupe consistant en :

- (a) FABF ou son fragment actif;
- (b) FABF ou son fragment actif et un anticorps anti- $\mu$ ;
- (c) FABF ou son fragment actif et un ligand de CD40 ; et
- (d) FABF ou son fragment actif et un anticorps monoclonal anti-ligand de CD40

pour la préparation d'une composition pharmaceutique pour stimuler la production d'immunoglobuline

3. Utilisation d'une composition sélectionnée dans le groupe consistant en :

- (a) FABF ou son fragment actif;
- (b) FABF ou son fragment actif et un anticorps anti- $\mu$ ;
- (c) FABF ou son fragment actif et un ligand de CD40 ; et
- (d) FABF ou son fragment actif et un anticorps monoclonal anti-ligand de CD40

pour la préparation d'une composition pharmaceutique pour co-stimuler la croissance des cellules B et la production d'immunoglobuline.

4. Utilisation d'une composition sélectionnée dans le groupe consistant en :

- (a) FABF ou son fragment actif;
- (b) FABF ou son fragment actif et un anticorps anti- $\mu$
- (c) FABF ou son fragment actif et un ligand de CD40 et
- (d) FABF ou son fragment actif et un anticorps monoclonal anti-ligand de CD40

pour la préparation d'une composition pharmaceutique pour stimuler la croissance et la maturation des cellules B induites par les cellules dendritiques.

- 5 5. Utilisation d'une composition comprenant un anticorps spécifique de FABF ou son fragment actif ou un anticorps spécifique d'un récepteur de FABF ou son épitope pour la préparation d'une composition pharmaceutique pour l'inhibition de la croissance des cellules B.
- 10 6. Utilisation d'une composition comprenant un anticorps spécifique de FABF ou son fragment actif ou un anticorps spécifique d'un récepteur de FABF ou son épitope pour la préparation d'une composition pharmaceutique pour inhiber la production d'immunoglobuline.
- 15 7. Utilisation d'une composition comprenant un anticorps spécifique de FABF ou son fragment actif ou un anticorps spécifique d'un récepteur de FABF ou son épitope pour la préparation d'une composition pharmaceutique pour co-inhiber la croissance des cellules B et la production d'immunoglobuline.
- 20 8. Utilisation d'une composition comprenant un anticorps spécifique de FABF ou son fragment actif ou un anticorps spécifique d'un récepteur de FABF ou son épitope pour la préparation d'une composition pharmaceutique pour inhiber la croissance et la maturation des cellules B induites par les cellules dendritiques.
- 20 9. Utilisation d'un anticorps spécifique de FABF ou son fragment actif, ou un anticorps spécifique d'un récepteur de FABF ou son épitope pour la préparation d'une composition pharmaceutique pour le traitement de l'hypertension.
10. Utilisation d'une composition sélectionnée dans le groupe consistant en :
  - 25 (a) FABF ou son fragment actif;
  - (b) FABF ou son fragment actif et un anticorps anti- $\mu$ ;
  - (c) FABF ou son fragment actif et un ligand de CD40;
  - (d) FABF ou son fragment actif et un anticorps monoclonal anti-ligand de CD40;
  - (e) un anticorps spécifique de FABF ou son fragment actif ; et
  - 30 (f) un anticorps spécifique d'un récepteur de FABF ou son épitope

pour la préparation d'une composition pharmaceutique pour le traitement d'une maladie auto-immune.

- 35 11. Utilisation selon l'une quelconque des revendications 1 à 4 et 10, où FABF est FABF soluble.
12. Utilisation selon la revendication 11, où FABF soluble est un FABF recombinant.
- 40 13. Utilisation selon l'une quelconque des revendications 5 à 10, où l'anticorps anti-FABF ou l'anticorps anti-récepteur de FABF est un anticorps monoclonal.
14. Utilisation d'un anticorps spécifique de FABF ou son fragment actif, ou d'un anticorps spécifique d'un récepteur de FABF ou son épitope, pour la préparation d'une composition pharmaceutique pour inhiber l'inflammation.
- 45 15. Utilisation de FABF ou son fragment actif pour la préparation d'une composition pharmaceutique pour réguler le développement des cellules hématopoïétiques.
16. Utilisation d'une composition sélectionnée dans le groupe consistant en :
  - 50 (a) FABF ou son fragment actif;
  - (b) FABF ou son fragment actif et un anticorps anti- $\mu$ ;
  - (c) FABF ou son fragment actif et un ligand de CD40;
  - (d) FABF ou son fragment actif et un anticorps monoclonal anti-ligand de CD40;
  - (e) un anticorps spécifique de FABF ou son fragment actif ; et
  - 55 (f) un anticorps spécifique d'un récepteur de FABF ou son épitope

pour la préparation d'une composition pharmaceutique pour stimuler la production des cellules B dans le traitement des maladies immunosuppressives.

## EP 1 146 892 B1

17. Utilisation selon la revendication 16, où la maladie immunosuppressive est VIH ou associée à une transplantation d'organe.

5

10

15

20

25

30

35


40

45

50

55

/

[illegible]

30




Figure 2




Figure 3






Figure 4




Figure 8




Fig. 6





Fig. 7A

**B**


**Control littermate**

802-26




**BAFF transgenic mice**

816-3




802-3



**B220**

Fig. 7B

Fig. 7C






Fig. 7D




Fig. 7E



Fig. 7F




Fig. 8A





Fig. 8B







Fig. 9A








Fig. 10AB

Fig. 10C





**Fig. 11.**






Fig. 12




Fig. 13

**Monday, June 6, 2005**

[illegible]

<b>Docket No.</b>	<b>Patent/Apl. No.</b>	<b>Description</b>
PF301D2	10/425,961	Draft ROA
PF189P1D1	10/994,679	IDS, as filed
PF189U1C1	10/135,839	IDS, as filed
PF189D5	10/232,686	IDS, as filed
PF189C1D2	10/791,905	IDS, as filed
PF189C1D1	10/127,764	IDS, as filed
PF189P1	10/067,800	IDS, as filed
PZ023P2	09/949,925	Updated Filing Receipt
PF403D2	10/733,646	Notice of Acceptance of Publication Request
PS901	10/664,357	Notice to File Missing Parts & Filing Receipt
	USP 6,849,436 B2	Certificate of Correction
	09/017,715	Notice of Allowance and Fee(s) Due w Exr's Amdt.
PF614PCT	PCT/US2005/009843	Notification of Receipt of Record Copy

<b>Docket No.</b>	<b>Patent/Appl. No.</b>	<b>Description</b>
1488.122EP10	EP 03 01 5456.1	Ltr. of advices and request for extension of time
PF174JP	08-534782	Rptg. ltr. from HellerEhrman to Genentech re. notice of appeal filed 5/30/05
PF131EP	Austrian Pat. #0799311	Ltr. rptg. filing of German translation by w/Debit Note
PF343KR	10-1999-7003614	Ltr. fwdg. KIPO Decision to Dismiss Notice of Appeal
PF375JP	503099/1999	Ltr. rptg. request for examination w/ debit note
PF115JP	529592/1995	Confirmation copy of e-mail dated 5/26/05 w/ Cert. Of Patent
PF574EP	02 79 9967.1	Ltr. fwdg. Search Report w/ attachments

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**